# VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 24 (24-31 octubre/2020)

## EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.



IFV INSTITUTO FINLAY DE VACUNAS SiViFinlay VaCyT

  

# Análisis bibliométrico sobre vacunas derivadas del análisis de los genomas: vacunología inversa

## Estrategia de búsqueda:

*TITLE: ("reverse vaccinology") 144 records*

**Periodo de estudio 2000-2020**

**Fuente de información utilizada:**

WEB OF SCIENCE™

Las variables utilizadas en el análisis fueron:

⇒ Productividad científica por año.

⇒ Autores con mayor productividad científica.

⇒ Revistas con mayor número de publicaciones sobre el tema.

⇒ Instituciones que han trabajado el tema de estudio.

⇒ Países a la vanguardia sobre el tema.

## Productividad científica por año




  

CUBA

## Autores con mayor productividad científica




## Revistas científicas que más han publicado sobre el tema




  

## Países de mayor producción científica en el tema




## Instituciones que más han trabajado el tema de estudio




  

# Noticias en la Web

## A vaccine helped end racial disparities in pneumococcal disease. There's hope a vaccine will do the same for Covid-19

**24 oct**. The world is focused on a Covid-19 vaccine to get everyone back to some version of normal, but the vaccine could also have another beneficial effect: It could reduce the disparities that have made the disease so deadly for some racial groups.

A recent study showed that a vaccine against pneumococcal disease erased racial differences in the rates of those infections. Pneumococcal bacteria cause potentially deadly types of pneumonia and meningitis, as well as heart and bloodstream infections.

"These results are amazing because they demonstrate that with the use of an effective vaccine, we in the US can reach out and literally eliminate disparities," said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center and co-author of the study, which was published in the Journal of Infectious Diseases.

There's hope a vaccine against the coronavirus could do the same for Covid-19 disparities, he said, but two concerns would need to be addressed.

First, the vaccine would need to be widely distributed to minority communities. Second, there would need to be education about the vaccine aimed specifically at minorities, who are especially hesitant to take it.

"We're going to have to look these hard truths in the face," Schaffner said.

**Vaccine made racial disparities disappear**

Before the introduction of a pneumococcal vaccine in 2010, Black people were approximately 1.5 times more likely than White people to get sick from pneumococcal infections, according to the Vanderbilt study.

There are many reasons for those differences, including genetic factors, comorbidities, overcrowding, hygiene conditions, nutrition and poverty, according to a 2014 editorial in Clinical Infectious Diseases.

The recent study looked at 20 Tennessee counties that represent 55% of the state's population. After the introduction of the vaccine, the incidence of pneumococcal disease declined overall, and differences between Blacks and Whites disappeared. White people actually had slightly higher rates of illness.

Schaffner said other parts of the country have likely seen similar results.

He attributed the success to vaccination of children, who receive pneumococcal vaccines at ages 2 months, 4 months, 6 months, and 12 to 15 months.

For more than 25 years, the Vaccines for Children program at the US Centers for Disease Control and Prevention has helped provide vaccines to children of all backgrounds, even if their parents can't afford them.

"We have the capacity to eliminate disparities in our current system when it's applied comprehensively and intelligently," said Schaffner, a member of the CDC's Advisory Committee on Immunization Practices.

**Unclear plans for getting Covid-19 vaccine to minority communities**

With no coronavirus vaccine available yet, there remain stark racial differences in who is impacted by Covid-19. Black people are 2.6 times more likely to get coronavirus than White people, and Latinos are 2.8 times more likely to catch the virus than White people, according to the US Centers for Disease Control and Prevention.

"Our goal is to ensure every American has easy access to a vaccine once available, and ensuring access to minority communities and medically underserved populations is a top priority," according to a

  

statement sent to CNN by a spokesperson for the Department of Health and Human Services.

It's unclear how the government intends to meet that goal.

Unlike the pneumococcal vaccine, the Covid-19 vaccine campaign will focus on adults at first, not children, and there's no program to ensure adults of all backgrounds have access to vaccines.

Last month, the CDC announced $200 million in funding to states for Covid-19 vaccine preparedness, but the agency's playbook for states to develop vaccine programs hardly mentions minority communities.

This week, an official with the Association of State and Territorial Health Officials said they still didn't have the federal money necessary to implement vaccine implementation plans.

Minorities have less access to health care, which could compromise their ability to get the vaccine once it's available.

"There are big time cost and distribution issues that need to be addressed," said Gary Puckrein, president of the National Minority Quality Forum.

It's also not completely clear that the vaccine will be free.

"We feel comfortable that our aspiration and the President's aspiration to provide vaccines to every American at zero out of pocket cost, that we're going to achieve that," Paul Mango, deputy chief of staff for policy at the US Department of Health and Human Services said at a telebriefing with reporters October 9.

**'A real need to build up confidence'**

Even if there's easy access to a free vaccine, there are questions about whether people of color will choose to take it.

Decades of discrimination and abuse by the health care system has left minorities, particularly Black people, mistrustful of doctors and scientific authorities.

Trust in the US Food and Drug Administration, which will authorize a vaccine, has been further eroded by a sense that the government is rushing the vaccine and forsaking safety, Puckrein said.

A recent poll shows Black people distrust a Covid-19 vaccine more than White people do.

A third of White people said they would shun a Covid-19 vaccine even if it were free and deemed safe and effective, but nearly half of Black people -- 49% -- said they would say no, according to the poll of 1,769 people conducted from August 20 through September 14 by the Kaiser Family Foundation and The Undefeated.

"The FDA's voice has been weakened quite frankly in terms of trust, so there will be a real need to build up confidence in minority populations," Puckrein said.

Fuente: CNN Health. Disponible en https://cutt.ly/WgDbF4g

## Ensayan una vacuna para prevenir cáncer de pulmón, intestino y páncreas

**25 oct**. Investigadores del Instituto Francis Crick de Londres han diseñado una vacuna para tratar y prevenir el cáncer de pulmón, intestino y páncreas, cuyos primeros ensayos en laboratorio con ratones han resultado prometedores.

Los investigadores tienen previsto presentar los resultados de este ensayo el próximo domingo en el 32º Simposio EORTC-NCI-AACR sobre dianas moleculares y terapéutica del cáncer, que se tenía que celebrar en Barcelona y que debido a la pandemia se llevará a cabo de manera virtual este fin de semana.

La vacuna ha sido creada para apuntar a un gen denominado KRAS, que está relacionado con el desarrollo de muchos tipos de cáncer, incluidos los de pulmón, intestino y páncreas.

  

El estudio de la vacuna ha sido llevado a cabo por la doctora Rachel Ambler, una investigadora posdoctoral, y otros investigadores en el Instituto Francis Crick de Londres.

"Sabemos que, si el gen KRAS falla, eso permite a las células que empiecen a multiplicarse y a convertirse en cancerígenas. Más recientemente, hemos aprendido que, con la ayuda adecuada, el sistema inmunitario puede ser capaz de ralentizar ese proceso", ha avanzado Ambler en un comunicado difundido por la organización del congreso.

"Queríamos ver si podíamos usar este conocimiento para crear una vacuna del cáncer que pudiera usarse no solo para tratarlo, sino para proporcionar una protección duradera contra la enfermedad y con efectos secundarios mínimos", ha añadido Ambler.

Los investigadores han creado un conjunto de vacunas que son capaces de suscitar una respuesta inmune contra la mayoría de las mutaciones KRAS más comunes.

Las vacunas están compuestas de dos elementos unidos, un fragmento de la proteína producida por las células del cáncer que tienen el gen KRAS mutado y un anticuerpo que ayuda a que la vacuna llegue a un tipo de célula del sistema inmune denominada dendrítica, que ayuda al sistema inmune a identificar y destruir células cancerígenas, una habilidad que las vacunas pueden reforzar.

Los investigadores han probado la vacuna en ratones que ya tenían tumores de pulmón y en otros a los que se les indujo el crecimiento de tumores.

Estudiaron los ratones para ver si sus sistemas inmunes respondían a la vacuna y también miraron si los tumores se reducían o no llegaban siquiera a formarse.

En los ratones con tumores, el 65% de los tratados con la vacuna seguían vivos 75 días después, en comparación con el 15% de aquellos que no la habían recibido.

En los ratones tratados para inducirles tumores, el 40% de los vacunados seguían libres de tumores 150 días después, en comparación con solo el 5% de los no vacunados (un ratón).

Al vacunar a los ratones, los investigadores hallaron que la aparición de tumores se veía retrasada de media 40 días.

"Cuando usamos la vacuna como tratamiento, vimos que ralentizaba el crecimiento de tumores en ratones. Y cuando la usamos como una medida de prevención, vimos que no aparecían tumores durante un tiempo bastante largo y que, en muchos casos, no llegaban a aparecer nunca", ha resumido Ambler.

Algunos ensayos previos de vacunas contra el cáncer han fallado, según cuenta, porque no fueron capaces de crear una respuesta lo suficientemente fuerte del sistema inmune que lograse hallar y destruir células cancerígenas.

"Esta investigación todavía tiene mucho trecho por recorrer antes de que pueda ayudar a prevenir y a tratar el cáncer en personas, pero nuestros resultados sugieren que el diseño de la vacuna ha creado una respuesta fuerte en los ratones, con muy pocos efectos secundarios", ha concluido.

Fuente: EFE. Disponible en https://cutt.ly/YgDnc4v

  

## Un instituto brasileño es autorizado a importar una vacuna china contra la COVID-19 rechazada por Bolsonaro

**24 oct**. El regulador brasileño Anvisa autorizó el viernes a un centro biomédico a importar 6 millones de dosis de la vacuna contra el coronavirus Sinovac, un día después de que el presidente Jair Bolsonaro dijera que Brasil no compraría la vacuna china.

El Instituto Butantan de São Paulo planea importar inicialmente la vacuna de Sinovac, que se encuentra en ensayos de fase 3 realizados con la ayuda de una universidad local y aún no está aprobada para un uso más amplio en Brasil. Butantan finalmente fabricaría la vacuna si se demuestra su eficacia.

El gobernador de São Paulo, João Doria, dijo el viernes que Anvisa le dijo que no cederá ante la presión política sobre la aprobación de posibles vacunas contra el coronavirus.

A principios de esta semana, Bolsonaro dijo en las redes sociales que Brasil no compraría la vacuna contra el coronavirus de Sinovac por aparentes preocupaciones políticas, luego de que sus partidarios lo cuestionaran sobre el tema.

Brasil tiene el segundo brote más mortal de COVID-19 después de Estados Unidos, con 156.471 muertos.

Fuente: Reuters. Disponible en https://cutt.ly/LgDPswJ

## Pfizer prueba una vacuna experimental de coronavirus en niños de 12 años

**26 oct**. La vacuna experimental contra el coronavirus de Pfizer se está probando ahora en el grupo de edad más joven: niños de hasta 12 años.

El cambio a probar la vacuna de coronavirus en niños más pequeños fue aprobado por la Administración de Medicinas y Alimentos de EE.UU. y las juntas de revisión institucional a principios de este mes, pero Pfizer dividió los grupos de niños en adolescentes mayores de 16 y 17 años y niños pequeños de 12 a 15 años.

Un equipo del Hospital de Niños de Cincinnati terminó de vacunar a 100 niños en el grupo de menores edad la semana pasada, dijo el Dr. Robert Frenck, quien dirige el ensayo de la vacuna contra el covid-19 de Pfizer en el hospital. La mitad de los voluntarios en esta tercera y última fase de la vacuna de Pfizer están recibiendo un placebo o inyección ficticia.

"Ahora estamos haciendo una pausa para observar las reacciones a la vacuna. En este momento estamos en una pausa planificada para asegurarnos de que todo sea lo más seguro posible ", dijo Frenck a CNN.

Entre los efectos secundarios que los médicos están observando se encuentran bultos, enrojecimiento o dolor en el lugar de la inyección, así como fiebre o dolor.

«Les pediría a otros niños que tomen la vacuna»

Abhinav, de 12 años, es uno de los niños voluntarios en las pruebas clínicas de la vacuna contra el coronavirus. El estudiante de séptimo grado, cuyos padres pidieron que solo se usara su nombre de pila para proteger su privacidad, espera que la vacunación generalizada ayude a que sus abuelos reanuden las visitas desde la India y que las clases vuelvan a la normalidad en la escuela.

«Creo que a todos en mi escuela les gustaría volver a la normalidad», dijo Abhinav a CNN. "Realmente creo que una vacuna podría prevenir la propagación de la infección. A partir de ahora, probablemente pediría a otros niños que la tomen».

La vacuna experimental es segura para los niños, dice Pfizer

Frenck dijo que la gente puede

  

estar nerviosa por darles a los niños una vacuna experimental contra el coronavirus, pero señaló que Pfizer ya se ha probado en decenas de miles de adultos.

"La razón por la que podemos usar esta vacuna en niños es que Pfizer tiene 30.000 adultos inscritos y tiene datos de seguridad de todas esas personas", dijo.

Además, dijo, será importante vacunar a los niños contra el coronavirus si hay alguna esperanza de controlar la pandemia. Es casi seguro que estén contribuyendo a la propagación silenciosa del virus.

«Creo que lo importante que la gente debe recordar es que, si bien los adolescentes no se enferman tanto como los adultos mayores, no significa que algunos niños no se enfermen y otros no se estén muriendo», dijo Frenck.

"Hasta ahora, 120 niños en Estados Unidos han muerto causa del covid".

Fuente: CNN en Español. Disponible en https://cutt.ly/8gDDnkJ

## Estudio demuestra que la vacuna de AstraZeneca y Oxford causa fuerte respuesta inmune

**26 oct**. la vacuna contra la COVID-19 de la Universidad de Oxford y AstraZeneca, ChAdOx1 n CoV-19 (también conocida como AZD1222), arrojó resultados satisfactorios acerca de seguir "con precisión" las instrucciones genéticas programadas por el equipo de científicos de la Universidad, así como la inducción de una "fuerte respuesta inmune.

El estudio evaluó la frecuencia y precisión con las que la potencial vacuna copia y lleva a cabo las instrucciones genéticas especificadas en ésta, las cuales incluyen cómo producir la proteína Spike del SARS-CoV-2.

La ChAdOx1 nCoV-19 se elaboró a partir de un virus del resfriado común (adenovirus) de chimpancés, eliminando el 20% de las instrucciones genéticas contenidas en el virus, proceso que impide su replicación o infección en seres humanos, pero permite su producción en laboratorios.

A partir de esta supresión, el virus cuenta con espacio para recibir nuevas instrucciones relacionadas con la proteína Spike y, una vez se encuentra en el organismo humano, se lleva a cabo un proceso conocido como transcripción, en que las instrucciones genéticas de la proteína Spike se "fotocopian" muchas veces.

De esta forma, el sistema inmunológico detecta la proteína del virus y reacciona en consecuencia, preentrenándose para una infección real de la COVID-19.

"Este es un estudio importante, ya que podemos confirmar que las instrucciones genéticas que sustentan esta vacuna, que se está desarrollando tan rápido como sea posible de forma segura, se siguen correctamente cuando entran en una célula humana", dijo el doctor David Matthews, lector de virología de la Escuela de Medicina Celular y Molecular de la Universidad de Bristol.

Fuente: Entrepreneur en Español. Disponible en https://cutt.ly/GgDFFO3

  

## Cuba approves clinical trial for Soberana 02 vaccine against Covid-19

**27 oct**. Cuba's Center for State Control of Medicines, Equipment and Medical Devices (CECMED) certified the phase I clinical trial for the vaccine candidate against Covid-19, Soberana 02, the Finlay Institute released on Tuesday.

'We are pleased to inform that CECMED approved the phase I clinical trial of the vaccine candidate Soberana 02, a mixed vaccine platform with backgrounds at the Finlay Institute, tweeted the institution specialized in the creation of vaccines.

'A know-how distinguishes us in the field of #preventive vaccines,' the message adds.

Recently, the director of the Finlay Institute, Vicente Verez, affirmed in an interview with the Granma newspaper that Soberana 02 is an innovative drug, as it has no precedents among all those developed to fight against the SARS-CoV-2 coronavirus, which causes Covid-19. As explained by the expert on that occasion, the novelty of this new candidate consists of being a mixed vaccine, in which the virus antigen, the receptor-binding domain (RBD), is chemically linked to the tetanus toxoid.

'We hope that the immunity of Soberana 02 reaches the mucous membrane of the respiratory tract to prevent the entry of the virus, and it will be the vaccine candidate that we will propose to apply in the pediatric population,' Verez stressed.

Fuente: Prensa Latina. Disponible en https://cutt.ly/3gDGLuY

## Sanofi y GSK apoyarán a COVAX con 200 millones de dosis de vacuna anticovid

**28 oct**. Sanofi y GSK firmaron una Declaración de Intenciones con Gavi, el administrador jurídico del Mecanismo COVAX, un mecanismo mundial de distribución de riesgos para la adquisición conjunta y la distribución equitativa de las eventuales vacunas contra COVID-19.

Sanofi y GSK tienen la intención de poner a disposición del Mecanismo COVAX 200 millones de dosis de su vacuna contra la COVID-19 a base de proteína recombinante y adyuvante, si las autoridades reguladoras lo aprueban y sujeto a contrato. Ambas empresas tienen la intención de contribuir a la ambición de COVAX de garantizar que las vacunas contra la COVID-19 que tengan éxito lleguen a quienes las necesitan, sean quienes sean y vivan donde vivan, una vez que obtengan las aprobaciones adecuadas.

“Para hacer frente a una crisis sanitaria mundial de esta magnitud, se necesitan asociaciones únicas. El compromiso que anunciamos hoy para el Mecanismo COVAX puede ayudarnos a tener juntos una mejor oportunidad de controlar la pandemia”, afirmó Thomas Triomphe, vicepresidente ejecutivo y director global de Sanofi Pasteur. “Este momento también refleja nuestro compromiso a largo plazo con la salud mundial y garantiza que nuestras vacunas COVID-19 sean asequibles y accesibles para las personas con mayor riesgo, en cualquier parte del mundo”.

  

Roger Connor, presidente de vacunas de GSK añadió: “Desde que empezamos a trabajar en el desarrollo de las vacunas contra la COVID-19, GSK se ha comprometido a ponerlas a disposición de personas en todo el mundo. Nos enorgullece trabajar con Sanofi para que esta vacuna basada en proteína recombinante con adyuvante esté disponible para los países firmantes del Mecanismo COVAX tan pronto como sea posible; esto tiene el potencial de ser una contribución significativa a la lucha mundial contra la COVID-19".

El Mecanismo COVAX forma parte de COVAX, una colaboración mundial de gobiernos, organizaciones sanitarias mundiales, empresas y organizaciones filantrópicas que trabajan para acelerar el desarrollo, la producción y el acceso equitativo a las vacunas contra COVID-19. COVAX está codirigido por Gavi, la Coalición para Innovaciones en la Preparación ante Epidemias (CEPI) y la OMS y constituye el pilar de las vacunas del Acelerador del Acceso a las herramientas contra la COVID-19 (Acelerador ACT). Recientemente, más de 180 países y economías se han adherido al Mecanismo COVAX para obtener un acceso oportuno y económico a las vacunas para hacer frente a la escala mundial de la pandemia de la COVID-19.

Gracias a los esfuerzos del Mecanismo COVAX, las vacunas se distribuirán en los países participantes a través del Marco de Asignación de la OMS, recientemente publicado, y del Marco de Valores del Grupo de Expertos en Asesoramiento Estratégico sobre Inmunización (SAGE) de la OMS, que ha comenzado a enmarcar la futura orientación sobre el uso de las vacunas. Estos principios de asignación tienen por objeto garantizar que las personas de todas partes del mundo tengan acceso a las vacunas contra la COVID-19 una vez que estén disponibles.

**Estado del desarrollo de la vacuna recombinante basada en proteínas adyuvantes**

Sanofi y GSK iniciaron un estudio de fase 1/2 el 3 de septiembre con un total de 440 individuos inscritos, y anticipan los primeros resultados a principios de diciembre del 2020, para apoyar el inicio de un estudio fundamental de fase 3 antes de que finalice el año. Si estos datos son suficientes para la solicitud de licencia, se prevé solicitar la aprobación reglamentaria a partir del primer semestre del 2021. Paralelamente, las empresas están aumentando la fabricación del antígeno y el adyuvante respectivamente.

**En las primeras líneas de la lucha contra la COVID-19**

Además de la vacuna basada en proteína recombinante en colaboración con GSK, Sanofi está desarrollando una vacuna de ARN mensajero con la compañía Translate Bio. Con varias plataformas de vacunas innovadoras que se están investigando en toda la industria, el ARNm es considerado entre los más prometedores. Los datos preclínicos muestran que dos inmunizaciones de la vacuna de ARNm indujeron altos niveles de anticuerpos neutralizantes que son comparables al rango superior de los observados en humanos infectados. Sanofi espera que el estudio de fase 1/2 inicie en el cuarto trimestre del 2020, con la posible aprobación más temprana en la segunda mitad del 2021. Translate Bio ha establecido la capacidad de fabricación de ARNm y Sanofi espera poder suministrar una capacidad anual de 90 a 360 millones de dosis.

Fuente: MundodeHoy.com . Disponible en https://cutt.ly/xgDHJUI

  

## El Reino Unido advirtió que las primeras vacunas contra el COVID-19 podrían ser imperfectas

**29 oct**. Luego de advertir que las primeras vacunas contra el coronavirus podrían ser imperfectas, la jefa del proyecto de Reino Unido para desarrollar una cura hizo un llamado el miércoles a la cooperación internacional inmediata para prevenir la "mayor recesión mundial de la historia".

Kate Bingham, quien dirige el grupo de trabajo que desarrolla la vacuna en Gran Bretaña, también pidió no caer en un exceso de optimismo debido a que, señaló, no hay una garantía de que se logre desarrollar una vacuna exitosa contra la COVID-19.

"Es probable que la primera generación de vacunas sea imperfecta y debemos estar preparados para que no prevengan la infección, sino que reduzcan los síntomas, e incluso entonces es posible que no funcionen para todos o por mucho tiempo", escribió Bingham en un ensayo publicado en la revista médica The Lancet.

Nunca se ha desarrollado una vacuna contra ningún coronavirus y numerosos intentos para diseñar tratamientos contra el SARS y el MERS, dos enfermedades relacionadas con el virus que causa la COVID-19, han fracasado. Los científicos también han advertido que la inmunidad contra los coronavirus parece desvanecerse con el paso del tiempo y que lograr cualquier inmunidad inducida por una vacuna para protegerse contra infecciones o enfermedades graves podría ser un desafío.

Sin embargo, diversos países, entre ellos Gran Bretaña, están basando sus estrategias para combatir a la COVID-19 en las expectativas de que una vacuna esté disponible a principios del próximo año.

El primer ministro británico, Boris Johnson, por ejemplo, ha implementado una estrategia regional de tres niveles que tiene como objetivo frenar la propagación de la enfermedad hasta que haya una vacuna y, al mismo tiempo, minimizar el daño económico que provocaría otro confinamiento generalizado.

Mientras tanto, los casos de coronavirus, las hospitalizaciones y las muertes en Reino Unido y en otras partes de Europa están aumentando en medio de una segunda ola de infecciones.

Gran Bretaña creó el grupo de trabajo hace unos meses para acelerar el desarrollo de una vacuna contra el coronavirus. Dos candidatas se encuentran en las últimas etapas de las pruebas y se prevé que los resultados estén listos para finales del año o principios de 2021. Decenas de otras posibles vacunas se encuentran en fases más tempranas de desarrollo.


Fuente: infobae. Disponible en https://cutt.ly/WgDV89S

## Lo que se sabe de la nueva variante del SARS-CoV-2 surgida en España

**31 oct**. Un análisis de la Universidad de Basilea, la Escuela Politécnica Federal de Zúrich y el consorcio español SeqCOVID-Spain, liderado por el Centro Superior de Investigaciones Científicas (CSIC), reveló este jueves que una nueva variante del coronavirus SARS-CoV-2 se expandió por Europa y otras regiones en los últimos meses desde España.

Los investigadores bautizaron esta mutación como "20A.EU1" y se logró confirmar su presencia en un 80 por ciento de las muestras

  

analizadas desde España, un 90 por ciento de las del Reino Unido y un 30-40 por ciento de las suizas.

Y aunque en su trabajo los científicos matizaron que esta variante del coronavirus no es más peligrosa que otras, puede no tener un comportamiento distinto o ser la única prevalente en la segunda oleada europea, donde otras mutaciones han sido identificadas, vale la pena profundizar en este hallazgo.

Por lo general, se asume que la mutación de los virus los torna más peligrosos y lo cierto es que estos cambios genéticos son muy frecuentes, según explica Carlos Álvarez, infectólogo y coordinador nacional de estudios covid-19 para la Organización Panamericana de la Salud (OPS).

De hecho, afirma que las alteraciones no suelen tener un efecto en su comportamiento, por lo que es muy poco probable que una mutación los vuelva más agresivos.

Lo mismo sucede con el SARS-CoV-2, al que diversas investigaciones ya le han encontrado cambios en su huella genética, como la hallada en España. "Estos pueden sonar alarmantes por la mala reputación de las mutaciones, pero no lo son", afirma el experto.

Álvarez insiste en que estos fenómenos son "comunes, normales y esperables de encontrar", y más en virus del tipo ARN (como los de influenza, el VIH y el SARS-CoV-2). En ese sentido afirma que los investigadores entienden que eso puede ocurrir y han estado alerta, tanto que al ser el virus más estudiado hasta ahora se ha demostrado que el coronavirus incluso muta menos que otros virus.

Y aclara que estas modificaciones naturales del virus no afectan el desarrollo de vacunas y tampoco la manera de enfrentar la pandemia de forma general. O en otras palabras, "no significa que para cada mutación tenga que existir una vacuna o un tratamiento para cada uno", remata Álvarez.

Fuente: EL TIEMPO. Disponible en https://cutt.ly/1gDBYbd

## Los tres principales modos de transmisión del SARS-COV-2

**31 oct**. Las gotículas, el contacto con las manos y las nubes de partículas virales (aerosoles) en espacios cerrados o mal ventilados son los principales modos de transmisión del nuevo coronavirus, que también puede sobrevivir nueve horas en la piel y hasta 28 días en las pantallas de los teléfonos.

El primer modo de transmisión de la COVID-19 identificado es el de las gotículas de saliva expulsadas por una persona infectada cuando tose o estornuda, pero también cuando canta o habla.

Los científicos creen que este tipo de contaminación requiere un contacto cercano, de entre un metro y un metro y medio. Por otro lado, estas gotas son relativamente «pesadas», caen rápidamente y no permanecen suspendidas en el aire.

El virus también puede adherirse a una superficie sucia por las gotículas, como manos, pañuelos, vasos, grifos, manijas de puertas, botones de ascensores o pasamanos. El riesgo de contaminación se produce al tocarse la cara después de tocar esas superficies.

El virus sobrevive nueve horas en la piel, en comparación con las 1,8 horas del virus de la gripe, según un estudio japonés publicado en la revista Clinical Infectious Diseases.

En las zonas cerradas y mal ventiladas, los aerosoles, esas nubes de gotitas microscópicas con partículas virales que se liberan con solo respirar, pueden recorrer mayores distancias y aterrizar directamente en las caras de otras personas en un perímetro de hasta casi dos metros.

Se desconoce la dosis de

  

partículas de virus necesaria para causar una infección, pero cuanto mayor sea la dosis, «mayor será la probabilidad de infección», dijo Steve Nigelle, un genetista especialista en Virología de la Universidad de Harvard.

«Hay tres modos de transmisión: gotitas, aerosoles y manuportaciones, sin saber la parte relativa de cada uno.

Así que tenemos que mantener todos los gestos barrera y abrir las ventanas», expresó el profe-

Fuente: Granma. Disponible en https://cutt.ly/ugDNrTK

**"Las gotículas, el contacto con las manos y las nubes de partículas virales (aerosoles) en espacios cerrados o mal ventilados son los principales modos de transmisión del nuevo coronavirus, que también puede sobrevivir nueve horas en la piel y hasta 28 días en las pantallas de los teléfonos ."**

## J&J comenzará a probar vacuna Covid-19 en adolescentes

**30 oct**. Johnson & Johnson planea comenzar a probar su vacuna experimental para el Covid-19 en jóvenes de 12 a 18 años lo antes posible, dijo un ejecutivo de la compañía en una reunión celebrada el viernes por los Centros para el Control y la Prevención de Enfermedades (CDC) de Estados Unidos.

"Planeamos comenzar con los niños tan pronto como podamos, pero con mucho cuidado en términos de seguridad", dijo el doctor Jerry Sadoff de J&J en una reunión virtual del Comité Asesor de Prácticas de Inmunización de los CDC.

Dependiendo de la seguridad y otros factores, la compañía planea hacer pruebas en niños aún más pequeños después, dijo Sadoff, un científico investigador de vacunas de la unidad Janssen de J&J.

J&J comenzó a probar la vacuna en adultos en un estudio de fase III de 60,000 voluntarios a finales de septiembre. Tuvo que detener las pruebas a principios de este mes debido a un grave evento médico ocurrido a uno de los participantes. El estudio se reanudó la semana pasada.

El fabricante rival Pfizer Inc. ya ha comenzado a probar la vacuna Covid-19 que está desarrollando con la alemana BioNTech en niños de tan sólo 12 años.

Fuente: Forbes México. Disponible en https://cutt.ly/FgDNvh7

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

FINLAY EDICIONES

  

**VacciMonitor** es una revista con más de 25 años de difundir los resultados científicos sobre vacunas de instituciones nacionales e internacionales y así coadyuvar a la visibilidad de este sector de la ciencia en Cuba y otros países, principalmente de Hispanoamérica. **http://vaccimonitor.finlay.edu.cu**

Está dedicada a la Vacunología y se incluyen temáticas de Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Programas de Vacunaciones, Estudios Preclínicos y Clínicos, Biología molecular, Bioinformática, Biomodelos Experimentales, Inmunodiagnosticadores, Tecnologías de Producción, Validación, Aseguramiento de la Calidad y Aspectos regulatorios.

Arbitrada, de acceso abierto y bajo la Licencia Creative Commons está indexada en:

**Visite también nuestra página @vaccimonitor**

  

# Artículos científicos publicados en Medline

*Filters activated: Publication date from 2020/10/24 to 2020/10/31. "Vaccine" (Title/Abstract) 237 records*

COVID-19 **Vaccine** Frontrunners and Their Nanotechnology Design.
Chung YH, Beiss V, Fiering SN, Steinmetz NF. ACS Nano. 2020 Oct 27;14(10):12522-12537. doi: 10.1021/acsnano.0c07197. Epub 2020 Oct 9. PMID: 33034449

Facial Masking for Covid-19 - Potential for "Variolation" as We Await a **Vaccine**.
Gandhi M, Rutherford GW. N Engl J Med. 2020 Oct 29;383(18):e101. doi: 10.1056/NEJMp2026913. Epub 2020 Sep 8. PMID: 32897661

Considering Emotion in COVID-19 **Vaccine** Communication: Addressing **Vaccine** Hesitancy and Fostering **Vaccine** Confidence.
Chou WS, Budenz A. Health Commun. 2020 Oct 30:1-5. doi: 10.1080/10410236.2020.1838096. Online ahead of print. PMID: 33124475

Spike mutation D614G alters SARS-CoV-2 fitness.
Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY. Nature. 2020 Oct 26. doi: 10.1038/s41586-020-2895-3. Online ahead of print. PMID: 33106671

The relationship between parental source of information and knowledge about measles / measles **vaccine** and **vaccine** hesitancy.
Ashkenazi S, Livni G, Klein A, Kremer N, Havlin A, Berkowitz O. Vaccine. 2020 Oct 27;38(46):7292-7298. doi: 10.1016/j.vaccine.2020.09.044. Epub 2020 Sep 25. PMID: 32981777

Engineering Antiviral Vaccines.
Zhou X, Jiang X, Qu M, Aninwene GE 2nd, Jucaud V, Moon JJ, Gu Z, Sun W, Khademhosseini A. ACS Nano. 2020 Oct 27;14(10):12370-12389. doi: 10.1021/acsnano.0c06109. Epub 2020 Oct 1. PMID: 33001626

Safety and efficacy of an attenuated heartwater (Ehrlichia ruminantium) **vaccine** administered by the intramuscular route in cattle, sheep and Angora goats.
Latif AA, Steyn HC, Josemans AI, Marumo RD, Pretorius A, Christo Troskie P, Combrink MP, Molepo LC, Haw A, Mbizeni S, Zweygarth E, Mans BJ. Vaccine. 2020 Oct 24:S0264-410X(20)31326-8. doi: 10.1016/j.vaccine.2020.10.032. Online ahead of print. PMID: 33109388

Chemical Strategies to Boost Cancer Vaccines.
Li WH, Li YM. Chem Rev. 2020 Oct 28;120(20):11420-11478. doi: 10.1021/acs.chemrev.9b00833. Epub 2020 Sep 11. PMID: 32914967

  

Influenza Vaccines toward Universality through Nanoplatforms and Given by Microneedle Patches.
Tang S, Zhu W, Wang BZ. Viruses. 2020 Oct 24;12(11):E1212. doi: 10.3390/v12111212. PMID: 33114336

Reduction in intestinal colonization and invasion of internal organs after challenge by homologous and heterologous serovars of Salmonella enterica following vaccination of chickens with a novel trivalent inactivated Salmonella **vaccine**.
Crouch CF, Pugh C, Patel A, Brink H, Wharmby C, Watts A, van Hulten MCW, de Vries SPW. Avian Pathol. 2020 Oct 29:1-12. doi: 10.1080/03079457.2020.1814200. Online ahead of print. PMID: 32907345

**Vaccine** mistrust among family healthcare professionals and **vaccine** hesitancy in the communities they serve in Turkey in 2019: a cross-sectional study.
Yörük S, Türkmen H, Durgut A, Erbek M. Hum Vaccin Immunother. 2020 Oct 29:1-8. doi: 10.1080/21645515.2020.1806671. Online ahead of print. PMID: 33121313

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein **vaccine** in healthy younger and older adults.
Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, Liu W, Sachs JR, Swenson CJ, Lee H, Cox KS, Spellman DS, Winstead CJ, Smolenov I, Lai E, Zaks T, Espeseth AS, Panther L. Hum Vaccin Immunother. 2020 Oct 29:1-14. doi: 10.1080/21645515.2020.1829899. Online ahead of print. PMID: 33121346

Protecting the Herd: Why Pharmacists Matter in Mass Vaccination.
Lee L, Peterson GM, Naunton M, Jackson S, Bushell M. Pharmacy (Basel). 2020 Oct 26;8(4):E199. doi: 10.3390/pharmacy8040199. PMID: 33114654

Feeling angry: the effects of **vaccine** misinformation and refutational messages on negative emotions and vaccination attitude.
Featherstone JD, Zhang J. J Health Commun. 2020 Oct 25:1-11. doi: 10.1080/10810730.2020.1838671. Online ahead of print. PMID: 33103600

Mass cytometry detects H3.3K27M-specific **vaccine** responses in diffuse midline glioma.
Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, Gilbert RD, Nazarian J, Molinaro AM, Butterfield LH, Prados MD, Okada H. J Clin Invest. 2020 Oct 26:140378. doi: 10.1172/JCI140378. Online ahead of print. PMID: 32817593

Is there a role for childhood vaccination against COVID-19?
Eberhardt CS, Siegrist CA. Pediatr Allergy Immunol. 2020 Oct 28. doi: 10.1111/pai.13401. Online ahead of print. PMID: 33113210

Understanding the reactogenicity of 4CMenB **vaccine**: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing.
Valente Pinto M, Davis K, Andrews N, Goldblatt D, Borrow R, Southern J, Nordgren IK, Vipond C, Plested E, Miller E, Snape MD. Vaccine. 2020 Oct 24:S0264-410X(20)31316-5. doi: 10.1016/j.vaccine.2020.10.023. Online ahead of print. PMID: 33109390

Attitudes of elite athletes and their support staff to the influenza **vaccine**.
O' Leary F, O' Donovan J. Ir J Med Sci. 2020 Oct 28. doi: 10.1007/s11845-020-02408-y. Online ahead of print. PMID: 33111253

Evaluating association of **vaccine** response to low serum zinc and vitamin D levels in children of a birth cohort study in Dhaka.
Das R, Jobayer Chisti M, Ahshanul Haque M, Ashraful Alam M, Das S, Mahfuz M, Mondal D, Ahmed T. Vaccine. 2020 Oct 26:S0264-410X(20)31352-9. doi: 10.1016/j.vaccine.2020.10.048. Online ahead of print. PMID: 33121844

Rhabdoviruses as vectors for vaccines and therapeutics.
Scher G, Schnell MJ. Curr Opin Virol. 2020 Oct 29;44:169-182. doi: 10.1016/j.coviro.2020.09.003. Online ahead of print. PMID: 33130500

COVID-19 in healthcare workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines.
Labetoulle R, Detoc M, Gagnaire J, Berthelot P, Pelissier C, Fontana L, Botelho-Nevers E, Gagneux-Brunon A. Expert Rev Vaccines. 2020 Oct 27. doi: 10.1080/14760584.2020.1843432. Online ahead of print. PMID: 33107353

Bone fractures during the time of coronavirus.
Umeda-Raffa S, Pergolizzi JV Jr, Raffa RB. J Clin Pharm Ther. 2020 Oct 26. doi: 10.1111/jcpt.13297. Online ahead of print. PMID: 33104253

Social media use and human papillomavirus awareness and knowledge among adults with children in the household: examining the role of race, ethnicity, and gender.
Lama Y, Quinn SC, Nan X, Cruz-Cano R. Hum Vaccin Immunother. 2020 Oct 29:1-11. doi: 10.1080/21645515.2020.1824498. Online ahead of print. PMID: 33121331

Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL$^{pro}$ Reporter Assay.
Froggatt HM, Heaton BE, Heaton NS. J Virol. 2020 Oct 27;94(22):e01265-20. doi: 10.1128/JVI.01265-20. Print 2020 Oct 27. PMID: 32843534

Pneumococcal Disease in Thailand.
Gamil A, Chokephaibulkit K, Phongsamart W, Techasaensiri C, Piralam B, Thamaree R. Int J Infect Dis. 2020 Oct 29:S1201-9712(20)32252-9. doi: 10.1016/j.ijid.2020.10.048. Online ahead of print. PMID: 33130205

Preparing for the **vaccine**.
[No authors listed] Nat Biotechnol. 2020 Oct 27:1. doi: 10.1038/s41587-020-0743-5. Online ahead of print. PMID: 33110209

Transforming **vaccine** development.
Black S, Bloom DE, Kaslow DC, Pecetta S, Rappuoli R. Semin Immunol. 2020 Oct 27:101413. doi: 10.1016/j.smim.2020.101413. Online ahead of print. PMID: 33127296

Engineering a vector-based pan-Leishmania **vaccine** for humans: proof of principle.
Cecílio P, Oristian J, Meneses C, Serafim TD, Valenzuela JG, Cordeiro da Silva A, Oliveira F. Sci Rep. 2020 Oct 29;10(1):18653. doi: 10.1038/s41598-020-75410-0. PMID: 33122717

SLy2-deficiency promotes B-1 cell immunity and triggers enhanced production of IgM and IgG(2) antibodies against pneumococcal **vaccine**.
Jaufmann J, Tümen L, Schmitt F, Schäll D, von Holleben M, Beer-Hammer S. Immun Inflamm Dis. 2020 Oct 24. doi: 10.1002/iid3.365. Online ahead of print. PMID: 33098380

Proton-driven transformable nanovaccine for cancer immunotherapy.
Gong N, Zhang Y, Teng X, Wang Y, Huo S, Qing G, Ni Q, Li X, Wang J, Ye X, Zhang T, Chen S, Wang Y, Yu J, Wang PC, Gan Y, Zhang J, Mitchell MJ, Li J, Liang XJ. Nat Nanotechnol. 2020 Oct 26. doi: 10.1038/s41565-020-00782-3. Online ahead of print. PMID: 33106640

Prospective safety surveillance study of ACAM2000 smallpox **vaccine** in deploying military personnel.
Faix DJ, Gordon DM, Perry LN, Raymond-Loher I, Tati N, Lin G, DiPietro G, Selmani A, Decker MD. Vaccine. 2020 Oct 27;38(46):7323-7330. doi: 10.1016/j.vaccine.2020.09.037. Epub 2020 Sep 20. PMID: 32967791

The Attenuated Pseudorabies Virus **Vaccine** Strain Bartha K61: A Brief Review on the Knowledge Gathered During 60 Years of Research.
Delva JL, Nauwynck HJ, Mettenleiter TC, Favoreel HW. Pathogens. 2020 Oct 27;9(11):E897. doi: 10.3390/pathogens9110897. PMID: 33121171

Predictors of influenza **vaccine** uptake: translation into Portuguese and validation of a questionnaire.
Neves CR, Codeço CT, Luz PM, Garcia LMT. Cad Saude Publica. 2020 Oct 26;36Suppl 2(Suppl 2):e00211518. doi: 10.1590/0102-311X00211518. eCollection 2020. PMID: 33111748

The development of a quarantine strategy is an important path to a normalized response to COVID-19.
Zhu H, Lu H. Biosci Trends. 2020 Oct 25. doi: 10.5582/bst.2020.03365. Online ahead of print. PMID: 33100292

The Impact of Climate Change on **Vaccine**-Preventable Diseases: Insights From Current Research and New Directions.
Mahmud AS, Martinez PP, He J, Baker RE. Curr Environ Health Rep. 2020 Oct 25:1-8. doi: 10.1007/s40572-020-00293-2. Online ahead of print. PMID: 33099754

Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis.
Elawar F, Oraby AK, Kieser Q, Jensen LD, Culp T, West FG, Marchant DJ. Pharmacol Ther. 2020 Oct 26:107712. doi: 10.1016/j.pharmthera.2020.107712. Online ahead of print. PMID: 33121940

What defines an efficacious COVID-19 **vaccine**? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. Lancet Infect Dis. 2020 Oct 27:S1473-3099(20)30773-8. doi: 10.1016/S1473-3099(20)30773-8. Online ahead of print. PMID: 33125914

Comparison of immunization systems in Japan and the United States - What can be learned?
Katsuta T, Moser CA, Feemster KA, Saitoh A, Offit PA. Vaccine. 2020 Oct 27;38(46):7401-7408. doi: 10.1016/j.vaccine.2020.09.028. Epub 2020 Sep 29. PMID: 33004240

A randomized controlled trial of an online immunization curriculum.
Pahud B, Elizabeth Williams S, Lee BR, Lewis KO, Middleton DB, Clark S, Humiston SG. Vaccine. 2020 Oct 27;38(46):7299-7307. doi: 10.1016/j.vaccine.2020.09.043. Epub 2020 Sep 26. PMID: 32988690

Overview of the possible role of vitamin C in management of COVID-19.
Abobaker A, Alzwi A, Alraied AHA. Pharmacol Rep. 2020 Oct 28:1-12. doi: 10.1007/s43440-020-00176-1. Online ahead of print. PMID: 33113146

Changes in circulating lymphocytes and lymphoid tissue associated with vaccination of colostrum deprived calves.
Falkenberg SM, Dassanayake RP, Palmer MV, Silveira S, Roth JA, Gauger E, Kaiser TJ, Guidarini C, Neill JD, Ridpath JF. Vaccine. 2020 Oct 27;38(46):7268-7277. doi: 10.1016/j.vaccine.2020.09.046. Epub 2020 Sep 26. PMID: 32988689

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.
Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, Hemmings O, O'Byrne A, Kouphou N, Galao RP, Betancor G, Wilson HD, Signell AW, Winstone H, Kerridge C, Huettner I, Jimenez-Guardeño JM, Lista MJ, Temperton N, Snell LB, Bisnauthsing K, Moore A, Green A, Martinez L, Stokes B, Honey J, Izquierdo-Barras A, Arbane G, Patel A, Tan MKI, O'Connell L, O'Hara G, MacMahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Shankar-Hari M, Edgeworth JD, Neil SJD, Malim MH, Doores KJ. Nat Microbiol. 2020 Oct 26. doi: 10.1038/s41564-020-00813-8. Online ahead of print. PMID: 33106674

Will vaccination refusal prolong the war on SARS-CoV-2?
Marcec R, Majta M, Likic R. Postgrad Med J. 2020 Oct 28:postgradmedj-2020-138903. doi: 10.1136/postgradmedj-2020-138903. Online ahead of print. PMID: 33115909

Therapeutic Efficacy of Phage $P_{IZ}$ SAE-01E2 against Abortion Caused by Salmonella enterica Serovar Abortusequi in Mice.
Wang X, Ji Y, Su J, Xue Y, Xi H, Wang Z, Bi L, Zhao R, Zhang H, Yang L, Guo Z, Guan Y, Feng X, Sun C, Lei L, Ur Rahman S, Dong J, Han W, Gu J. Appl Environ Microbiol. 2020 Oct 28;86(22):e01366-20. doi: 10.1128/AEM.01366-20. Print 2020 Oct 28. PMID: 32887718

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs.
Golay J, Taylor RP. Antibodies (Basel). 2020 Oct 28;9(4):E58. doi: 10.3390/antib9040058. PMID: 33126570

Progress Toward Global Eradication of Dracunculiasis, January 2019-June 2020.
Hopkins DR, Weiss AJ, Roy SL, Yerian S, Sapp SGH. MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1563-1568. doi: 10.15585/mmwr.mm6943a2. PMID: 33119555

New tuberculosis vaccines: advances in clinical development and modelling.
Weerasuriya CK, Clark RA, White RG, Harris RC. J Intern Med. 2020 Oct 31. doi: 10.1111/joim.13197. Online ahead of print. PMID: 33128834

EFFECTS OF IMMUNIZATION PROGRAM ON MORBIDITY AND MORTALITY OF **VACCINE**-PREVENTABLE DISEASES IN TURKEY.
Nayİr T, Nazlican E, Şahİn M, Kara F, Alp MeŞe E. Turk J Med Sci. 2020 Oct 31. doi: 10.3906/sag-2008-177. Online ahead of print. PMID: 33128356

Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.
Staudt RP, Alvarado JJ, Emert-Sedlak LA, Shi H, Shu ST, Wales TE, Engen JR, Smithgall TE. J Biol Chem. 2020 Oct 30;295(44):15158-15171. doi: 10.1074/jbc.REV120.012317. Epub 2020 Aug 29. PMID: 32862141

Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus **vaccine** (LLR3) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial.
Xia S, Du J, Su J, Liu Y, Huang L, Yu Q, Xie Z, Gao J, Xu B, Gao X, Guo T, Liu Y, Zhou X, Yang H. Vaccine. 2020 Oct 27;38(46):7393-7400. doi: 10.1016/j.vaccine.2020.04.038. Epub 2020 May 23. PMID: 32451212

A Synthetic Carbohydrate-Protein Conjugate **Vaccine** Candidate against Klebsiella pneumoniae Serotype K2.
Ravinder M, Liao KS, Cheng YY, Pawar S, Lin TL, Wang JT, Wu CY. J Org Chem. 2020 Oct 27. doi: 10.1021/acs.joc.0c01404. Online ahead of print. PMID: 33108196

Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus **vaccine** (Hantavax): A multi-center phase III clinical trial in healthy adults.
Song JY, Jeong HW, Yun JW, Lee J, Woo HJ, Bae JY, Park MS, Choi WS, Park DW, Noh JY, Cheong HJ, Kim WJ. Vaccine. 2020 Oct 29:S0264-410X(20)31329-3. doi: 10.1016/j.vaccine.2020.10.035. Online ahead of print. PMID: 33131933

Immunization with oral and parenteral subunit chimeric **vaccine** candidate confers protection against Necrotic Enteritis in chickens.
Katalani C, Ahmadian G, Nematzadeh G, Amani J, Ehsani P, Razmyar J, Kiani G. Vaccine. 2020 Oct 27;38(46):7284-7291. doi: 10.1016/j.vaccine.2020.09.047. Epub 2020 Oct 2. PMID: 33012608

First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria **vaccine** BK-SE36 with CpG-ODN(K3).
Ezoe S, Palacpac NMQ, Tetsutani K, Yamamoto K, Okada K, Taira M, Nishida S, Hirata H, Ogata A, Yamada T, Yagi M, Edula JR, Oishi Y, Tougan T, Ishii KJ, Myoui A, Horii T. Vaccine. 2020 Oct 27;38(46):7246-7257. doi: 10.1016/j.vaccine.2020.09.056. Epub 2020 Oct 2. PMID: 33012605

Interventions to reduce the burden of **vaccine**-preventable diseases among migrants and refugees worldwide: A scoping review of published literature, 2006-2018.
Charania NA, Gaze N, Kung JY, Brooks S. Vaccine. 2020 Oct 27;38(46):7217-7225. doi: 10.1016/j.vaccine.2020.09.054. Epub 2020 Sep 30. PMID: 33008670

Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study.
Tozawa-Ono A, Kamada M, Teramoto K, Hareyama H, Kodama S, Kasai T, Iwanari O, Koizumi T, Ozawa N, Suzuki M, Kinoshita K. Hum Vaccin Immunother. 2020 Oct 29:1-5. doi: 10.1080/21645515.2020.1817715. Online ahead of print. PMID: 33121340

Vaccines for neglected and emerging diseases in Brazil by 2030: the "valley of death" and opportunities for RD&I in Vaccinology 4.0.
Homma A, Freire MDS, Possas C. Cad Saude Publica. 2020 Oct 26;36Suppl 2(Suppl 2):e00128819. doi: 10.1590/0102-311X00128819. eCollection 2020. PMID: 33111747

The effects of manufacture processes on post-translational modifications of bioactive proteins in pertussis **vaccine**.
Long Z, Wei C, Zhan Z, Li X, Li Y, Ma X, Li C, Wang L, Huang T. J Pharm Biomed Anal. 2020 Oct 25;190:113536. doi: 10.1016/j.jpba.2020.113536. Epub 2020 Aug 15. PMID: 32858414

Efficacy, safety, and formulation issues of the combined vaccines.
Tafreshi SH. Expert Rev Vaccines. 2020 Oct 29. doi: 10.1080/14760584.2020.1843434. Online ahead of print. PMID: 33118470

The Italian arm of the PREPARE study: an international project to evaluate and license a maternal **vaccine** against group B streptococcus.
Berardi A, Cassetti T, Creti R, Vocale C, Ambretti S, Sarti M, Facchinetti F, Cose S; Prepare Network, Heath P, Le Doare K. Ital J Pediatr. 2020 Oct 28;46(1):160. doi: 10.1186/s13052-020-00923-3. PMID: 33115542

The Changing Landscape of Therapeutic Cancer Vaccines - Novel Platforms and Neoantigen Identification.
Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW. Clin Cancer Res. 2020 Oct 29:clincanres.0245.2020. doi: 10.1158/1078-0432.CCR-20-0245. Online ahead of print. PMID: 33122346

Planetary Health Humanities-Responding to COVID Times.
Lewis B. J Med Humanit. 2020 Oct 28:1-14. doi: 10.1007/s10912-020-09670-2. Online ahead of print. PMID: 33111198

Parent, provider and vaccinee preferences for HPV vaccination: A systematic review of discrete choice experiments.
Lack A, Hiligsmann M, Bloem P, Tünneßen M, Hutubessy R. Vaccine. 2020 Oct 27;38(46):7226-7238. doi: 10.1016/j.vaccine.2020.08.078. Epub 2020 Oct 3. PMID: 33023774

Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan.
Hoshi SL, Shono A, Seposo X, Okubo I, Kondo M. Vaccine. 2020 Oct 27;38(46):7363-7371. doi: 10.1016/j.vaccine.2020.09.024. Epub 2020 Oct 2. PMID: 33020012

Comparative Evaluation of Prophylactic SIV Vaccination Modalities Administered to the Oral Cavity.
Chaudhary O, Wang L, Bose D, Narayan V, Yeh MT, Carville A, Clements JD, Andino R, Kozlowski PA, Aldovini A. AIDS Res Hum Retroviruses. 2020 Oct 27. doi: 10.1089/AID.2020.0157. Online ahead of print. PMID: 32962398

Pneumococcal colonization among healthy and hospitalized **vaccine**-naive Sri Lankan children.
Vidanapathirana G, Angulmaduwa S, Munasinghe T, Ekanayake A, Kudagammana T, Dissanayaka N, Liyanapathirana V. Vaccine. 2020 Oct 27;38(46):7308-7315. doi: 10.1016/j.vaccine.2020.09.040. Epub 2020 Sep 25. PMID: 32981783

Development and validation of an assay for detection of Japanese encephalitis virus specific antibody responses.
Pushpakumara PD, Jeewandara C, Gomes L, Perera Y, Wijewickrama A, Malavige GN, Goonesekara C. PLoS One. 2020 Oct 28;15(10):e0238609. doi: 10.1371/journal.pone.0238609. eCollection 2020. PMID: 33112881

Knowledge, Attitude, and Practice Towards COVID-19 Among People Living with HIV/AIDS in Kigali, Rwanda.
Iradukunda PG, Pierre G, Muhozi V, Denhere K, Dzinamarira T. J Community Health. 2020 Oct 26:1-6. doi: 10.1007/s10900-020-00938-1. Online ahead of print. PMID: 33106963

Prioritizing Healthcare and Employment Resources during COVID-19: Roles of Benevolent and Hostile Ageism.
Apriceno M, Lytle A, Monahan C, Macdonald J, Levy SR. Gerontologist. 2020 Oct 29:gnaa165. doi: 10.1093/geront/gnaa165. Online ahead of print. PMID: 33119089

Antibody Response of a H9 Subtype Avian Influenza Poultry **Vaccine** on Three Kinds of Wild Birds in Shanghai Zoo.
Wang Y, Chen X, Yuan Y. Avian Dis. 2020 Oct 27. doi: 10.1637/aviandiseases-D-20-00094. Online ahead of print. PMID: 33108447

A **vaccine** to prevent egg layer peritonitis in chickens.
Cox GJ, Griffith B, Reed M, Sandstrom JD, Peterson MP, Emery D, Straub DE. Avian Dis. 2020 Oct 30. doi: 10.1637/aviandiseases-D-20-00093. Online ahead of print. PMID: 33125038

Lowering the recommended age for the free and active offer of influenza vaccination in Italy: clinical and economic impact analysis in the Liguria region.
Trucchi C, D'Amelio M, Amicizia D, Orsi A, Loiacono I, Tosatto R, Piazza MF, Paganino C, Pitrelli A, Icardi G, Ansaldi F. Hum Vaccin Immunother. 2020 Oct 29:1-9. doi: 10.1080/21645515.2020.1810494. Online ahead of print. PMID: 33121342

Informed consent disclosure to **vaccine** trial subjects of risk of COVID-19 vaccines worsening clinical disease.
Cardozo T, Veazey R. Int J Clin Pract. 2020 Oct 28:e13795. doi: 10.1111/ijcp.13795. Online ahead of print. PMID: 33113270

Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
Pierce BG, Keck ZY, Wang R, Lau P, Garagusi K, Elkholy K, Toth EA, Urbanowicz RA, Guest JD, Agnihotri P, Kerzic MC, Marin A, Andrianov AK, Ball JK, Mariuzza RA, Fuerst TR, Foung SKH. J Virol. 2020 Oct 27;94(22):e00704-20. doi: 10.1128/JVI.00704-20. Print 2020 Oct 27. PMID: 32878891

Prediction and evolution of B cell epitopes of surface protein in SARS-CoV-2.
Lon JR, Bai Y, Zhong B, Cai F, Du H. Virol J. 2020 Oct 29;17(1):165. doi: 10.1186/s12985-020-01437-4. PMID: 33121513

Prevalence and Bayesian Phylogenetics of Enteroviruses Derived From Environmental Surveillance Around Polio **Vaccine** Switch Period in Shandong Province, China.
Zhao C, Lin X, Ji F, Xiong P, Liu Y, Wang S, Chen P, Xu Q, Zhang L, Tao Z, Xu A. Food Environ Virol. 2020 Oct 27. doi: 10.1007/s12560-020-09449-7. Online ahead of print. PMID: 33108600

Cotton Rat Placenta Anatomy and Fc Receptor Expression and Their Roles in Maternal Antibody Transfer.
Martinez ME, Niewiesk S, La Perle KMD. Comp Med. 2020 Oct 29. doi: 10.30802/AALAS-CM-20-000040. Online ahead of print. PMID: 33121562

Increasing vaccination coverage: The school entry vaccination record check program in Guizhou Province China, 2003-2018.
Zuo S, Zhang D, Mu Q, Dai L, Du W, Xu F, Feng J, Heffelfinger JD. Vaccine. 2020 Oct 27;38(46):7379-7383. doi: 10.1016/j.vaccine.2020.08.055. Epub 2020 Sep 3. PMID: 32891472

Home collection of nasal swabs for detection of influenza in the Household Influenza **Vaccine** Evaluation Study.
Malosh RE, Petrie JG, Callear AP, Monto AS, Martin ET. Influenza Other Respir Viruses. 2020 Oct 26. doi: 10.1111/irv.12822. Online ahead of print. PMID: 33107200

Antibody Correlates of Protection from Clinical *Plasmodium falciparum* Malaria in an Area of Low and Unstable Malaria Transmission.
Hamre KES, Ondigo BN, Hodges JS, Dutta S, Theisen M, Ayodo G, John CC. Am J Trop Med Hyg. 2020 Oct 27. doi: 10.4269/ajtmh.18-0805. Online ahead of print. PMID: 33124533

Current and historic HIV-1 molecular epidemiology in paediatric and adult population from Kinshasa in the Democratic Republic of Congo.
Rubio-Garrido M, González-Alba JM, Reina G, Ndarabu A, Barquín D, Carlos S, Galán JC, Holguín Á. Sci Rep. 2020 Oct 28;10(1):18461. doi: 10.1038/s41598-020-74558-z. PMID: 33116151

Innate local response and tissue recovery following application of high density microarray patches to human skin.
Muller DA, Henricson J, Baker SB, Togö T, Jayashi Flores CM, Lemaire PA, Forster A, Anderson CD. Sci Rep. 2020 Oct 28;10(1):18468. doi: 10.1038/s41598-020-75169-4. PMID: 33116241

Pneumococcal conjugate **vaccine** primes mucosal immune responses to pneumococcal polysaccharide **vaccine** booster in Papua New Guinean children.

Orami T, Ford R, Kirkham LA, Thornton R, Corscadden K, Richmond PC, Pomat WS, van den Biggelaar AHJ, Lehmann D; Neonatal Pneumococcal Conjugate Vaccine Trial team. Vaccine. 2020 Oct 26:S0264-410X(20)31336-0. doi: 10.1016/j.vaccine.2020.10.042. Online ahead of print. PMID: 33121845

Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation.
Bricker KM, Obregon-Perko V, Uddin F, Williams B, Uffman EA, Garrido C, Fouda GG, Geleziunas R, Robb M, Michael N, Barouch DH, Chahroudi A. PLoS Pathog. 2020 Oct 26;16(10):e1008954. doi: 10.1371/journal.ppat.1008954. Online ahead of print. PMID: 33104758

Assessing COVID-19 **vaccine** literacy: a preliminary online survey.
Biasio LR, Bonaccorsi G, Lorini C, Pecorelli S. Hum Vaccin Immunother. 2020 Oct 29:1-9. doi: 10.1080/21645515.2020.1829315. Online ahead of print. PMID: 33118868

Evaluation of changes in the epidemiology of leptospirosis in dogs after introduction of a quadrivalent antileptospiral **vaccine** in a highly endemic area.
Francey T, Schweighauser A, Reber A, Schuller S. J Vet Intern Med. 2020 Oct 26. doi: 10.1111/jvim.15947. Online ahead of print. PMID: 33103800

Deciphering Vaccines for COVID-19: where do we stand today?
Baviskar T, Raut D, Bhatt LK. Immunopharmacol Immunotoxicol. 2020 Oct 25:1-14. doi: 10.1080/08923973.2020.1837867. Online ahead of print. PMID: 33054486

Immunization of human hepatitis E viruses conferred protection against challenge by a camel hepatitis E virus.
Guo Y, Yang F, Xu X, Feng M, Liao Y, He Z, Takeda N, Muramatsu M, Li Q, Li TC. Vaccine. 2020 Oct 27;38(46):7316-7322. doi: 10.1016/j.vaccine.2020.09.036. Epub 2020 Sep 23. PMID: 32980200

Identification and Isolation of Two Different Subpopulations Within African Swine Fever Virus Arm/07 Stock.
Pérez-Núñez D, Castillo-Rosa E, Vigara-Astillero G, García-Belmonte R, Gallardo C, Revilla Y. Vaccines (Basel). 2020 Oct 25;8(4):E625. doi: 10.3390/vaccines8040625. PMID: 33113838

Equine influenza vaccination in the UK- current practices may leave horses with suboptimal immunity.
Wilson A, Pinchbeck G, Dean R, McGowan C. Equine Vet J. 2020 Oct 30. doi: 10.1111/evj.13377. Online ahead of print. PMID: 33124070

COVID19 in the Least Developed Fragile and Conflict-Affected Countries - How Can the Most Vulnerable be Protected?
Ebrahim SH, Gozzer E, Ahmed Y, Imtiaz R, Ditekemena J, Rahman NMM, Schlagenhauf P, Alqahtani SA, Memish ZA. Int J Infect Dis. 2020 Oct 29:S1201-9712(20)32259-1. doi: 10.1016/j.ijid.2020.10.055. Online ahead of print. PMID: 33130196

CoVID-19: Parent and caregiver concerns about reopening New Zealand schools.
Jeffs E, Lucas N, Walls T. J Paediatr Child Health. 2020 Oct 28. doi: 10.1111/jpc.15234. Online ahead of print. PMID: 33112012

The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.
Agoni C, Soliman MES. Curr Pharm Biotechnol. 2020 Oct 27. doi: 10.2174/1389201021666201027154833. Online ahead of print. PMID: 33109039

Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
Chesson HW, Meites E, Ekwueme DU, Saraiya M, Markowitz LE. Vaccine. 2020 Oct 26:S0264-410X(20)31312-8. doi: 10.1016/j.vaccine.2020.10.019. Online ahead of print. PMID: 33121846

SARS-CoV-2 **vaccine** candidates in rapid development.
Li L, Guo P, Zhang X, Yu Z, Zhang W, Sun H. Hum Vaccin Immunother. 2020 Oct 29:1-10. doi: 10.1080/21645515.2020.1804777. Online ahead of print. PMID: 33121319

How to recover lost **vaccine** acceptance? A multi-center survey on HPV **vaccine** acceptance in Japan.
Mizumachi K, Aoki H, Kitano T, Onishi T, Takeyama M, Shima M. J Infect Chemother. 2020 Oct 27:S1341-321X(20)30371-8. doi: 10.1016/j.jiac.2020.10.012. Online ahead of print. PMID: 33127289

A Web Application About Herd Immunity Using Personalized Avatars: Development Study.
Hakim H, Bettinger JA, Chambers CT, Driedger SM, Dubé E, Gavaruzzi T, Giguere AMC, Kavanagh É, Leask J, MacDonald SE, Orji R, Parent E, Paquette JS, Roberge J, Sander B, Scherer AM, Tremblay-Breault M, Wilson K, Reinharz D, Witteman HO. J Med Internet Res. 2020 Oct 30;22(10):e20113. doi: 10.2196/20113. PMID: 33124994

Risk Assessment of therapeutic agents under consideration to treat COVID-19 in Pediatric Patients and Pregnant Women.
Barrett JS. Br J Clin Pharmacol. 2020 Oct 30. doi: 10.1111/bcp.14630. Online ahead of print. PMID: 33125791

Staphylococcal Protein A (*spa*) Locus Is a Hot Spot for Recombination and Horizontal Gene Transfer in Staphylococcus pseudintermedius.
Zukancic A, Khan MA, Gurmen SJ, Gliniecki QM, Moritz-Kinkade DL, Maddox CW, Alam MT. mSphere. 2020 Oct 28;5(5):e00666-20. doi: 10.1128/mSphere.00666-20. PMID: 33115833

HPV **vaccine** acceptability and willingness-related factors among Chinese adolescents: a nation-wide study.
Zhang X, Wang Z, Ren Z, Li Z, Ma W, Gao X, Zhang R, Qiao Y, Li J. Hum Vaccin Immunother. 2020 Oct 29:1-8. doi: 10.1080/21645515.2020.1812314. Online ahead of print. PMID: 33121330

Natural phyto, compounds as possible noncovalent inhibitors against SARS-CoV2 protease: computational approach.
Ogidigo JO, Iwuchukwu EA, Ibeji CU, Okpalefe O, Soliman MES. J Biomol Struct Dyn. 2020 Oct 25:1-18. doi: 10.1080/07391102.2020.1837681. Online ahead of print. PMID: 33103616

Facilitators and barriers to engagement with contact tracing during infectious disease outbreaks: A rapid review of the evidence.
Megnin-Viggars O, Carter P, Melendez-Torres GJ, Weston D, Rubin GJ. PLoS One. 2020 Oct 29;15(10):e0241473. doi: 10.1371/journal.pone.0241473. eCollection 2020. PMID: 33120402

Diphtheria-tetanus-pertussis (DTP) **vaccine** is associated with increased female-male mortality rate ratios. A meta-analysis of studies of DTP administered before and after measles **vaccine**.
Hanifi SMA, Fisker AB, Welaga P, Rieckmann A, Jensen AG, Benn CS, Aaby P. J Infect Dis. 2020 Oct 30:jiaa684. doi: 10.1093/infdis/jiaa684. Online ahead of print. PMID: 33125458

Isolation, identification and chemical inactivation of infectious laryngotracheitis virus for use as a **vaccine** candidate.
Ebrahimi MM, Shahsavandi S, Yousefi AR, Ebrahimi N. Acta Virol. 2020 Oct 28. doi: 10.4149/av_2021_101. Online ahead of print. PMID: 33112636

Microneedles: Characteristics, Materials, Production Methods and Commercial Development.
Tucak A, Sirbubalo M, Hindija L, Rahić O, Hadžiabdić J, Muhamedagić K, Čekić A, Vranić E. Micromachines (Basel). 2020 Oct 27;11(11):E961. doi: 10.3390/mi11110961. PMID: 33121041

Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection.
Files JK, Boppana S, Perez MD, Sarkar S, Lowman KE, Qin K, Sterrett S, Carlin E, Bansal A, Sabbaj S, Long DM, Kutsch O, Kobie J, Goepfert P, Erdmann N. J Clin Invest. 2020 Oct 29:140491. doi: 10.1172/JCI140491. Online ahead of print. PMID: 33119547

Elimination of cervical cancer in low- and middle-income countries: Inequality of access and fragile healthcare systems.
Vale DB, Teixeira JC, Bragança JF, Derchain S, Sarian LO, Zeferino LC. Int J Gynaecol Obstet. 2020 Oct 31. doi: 10.1002/ijgo.13458. Online ahead of print. PMID: 33128771

SARS-CoV-2 specific T-cells Are Rapidly Expanded for Therapeutic Use and Target Conserved Regions of Membrane Protein.
Keller MD, Harris KM, Jensen-Wachspress MA, Kankate V, Lang H, Lazarski CA, Durkee-Shock JR, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson E, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem UO, Stanojevic M, Geiger AE, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CRY, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM. Blood. 2020 Oct 26:blood.2020008488. doi: 10.1182/blood.2020008488. Online ahead of print. PMID: 33104167

Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice.
Ponndorf D, Meshcheriakova Y, Thuenemann E, Alonso AD, Overman R, Holton N, Dowall S, Kennedy E, Stocks M, Lomonossoff G, Peyret H. Plant Biotechnol J. 2020 Oct 25. doi: 10.1111/pbi.13501. Online ahead of print. PMID: 33099859

Bacillus Calmette-Guerin (BCG) **Vaccine**-associated Complications in Immunodeficient Patients Following Stem Cell Transplantation.
NaserEddin A, Dinur-Schejter Y, Shadur B, Zaidman I, Even-Or E, Averbuch D, Shamriz O, Tal Y, Shaag A, Warnatz K, Elpeleg O, Stepensky P. J Clin Immunol. 2020 Oct 27:1-16. doi: 10.1007/s10875-020-00892-6. Online ahead of print. PMID: 33111199

Replication of small ruminant lentiviruses in aluminum hydroxide-induced granulomas in sheep: a potential new factor for viral dissemination.
Echeverría I, de Miguel R, Asín J, Rodríguez-Largo A, Fernández A, Pérez M, de Andrés D, Luján L, Reina R. J Virol. 2020 Oct 28:JVI.01859-20. doi: 10.1128/JVI.01859-20. Online ahead of print. PMID: 33115880

FDA Emergency Use Authorization: Glass Half Empty?
Guharoy R, Krenzelok EP. Clin Infect Dis. 2020 Oct 26:ciaa1653. doi: 10.1093/cid/ciaa1653. Online ahead of print. PMID: 33104216

Specialized Proresolving Mediators Overcome Immune Suppression Induced by Exposure to Secondhand Smoke.
Bhat TA, Kalathil SG, Miller A, Thatcher TH, Sime PJ, Thanavala Y. J Immunol. 2020 Oct 28:ji2000711. doi: 10.4049/jimmunol.2000711. Online ahead of print. PMID: 33115852

A Phase I Open-Label Clinical Trial Evaluating the Therapeutic **Vaccine** hVEGF26-104/RFASE in Patients with Advanced Solid Malignancies.
Goedegebuure RSA, Wentink MQ, van der Vliet HJ, Timmerman P, Griffioen AW, de Gruijl TD, Verheul HMW. Oncologist. 2020 Oct 26. doi: 10.1002/onco.13576. Online ahead of print. PMID: 33105058

Use of a comprehensive program to review religious and personal seasonal influenza vaccination exemption requests by healthcare personnel.
Boone BC, Johnson RT, Rolando LA, Talbot TR. Infect Control Hosp Epidemiol. 2020 Oct 29:1-6. doi: 10.1017/ice.2020.1260. Online ahead of print. PMID: 33118915

Incidence of Mumps Deafness in Japan, 2005-2017: Analysis of Japanese Insurance Claims Database.
Takagi A, Ohfuji S, Nakano T, Kumihashi H, Kano M, Tanaka T. J Epidemiol. 2020 Oct 24. doi: 10.2188/jea.JE20200233. Online ahead of print. PMID: 33100297

Incidence and mortality of pertussis disease in infants <12 months of age following introduction of pertussis maternal universal mass vaccination in Bogotá, Colombia.
Carrasquilla G, Porras A, Martinez S, DeAntonio R, Devadiga R, Caceres DC, Juliao P. Vaccine. 2020 Oct 27;38(46):7384-7392. doi: 10.1016/j.vaccine.2020.07.046. Epub 2020 Oct 2. PMID: 33012607

Patterns in Wealth-related Inequalities in 86 Low- and Middle-Income Countries: Global Evidence on the Emergence of **Vaccine** Hesitancy.
Cata-Preta BO, Wehrmeister FC, Santos TM, Barros AJD, Victora CG. Am J Prev Med. 2020 Oct 29:S0749-3797(20)30395-0. doi: 10.1016/j.amepre.2020.07.028. Online ahead of print. PMID: 33131990

  

Escalation and de-escalation of the radiology response to COVID-19 in a tertiary hospital in South London: The King's College Hospital experience.
Panayiotou A, Rafailidis V, Puttick T, Satchithananda K, Gray A, Sidhu PS. Br J Radiol. 2020 Oct 28:20201034. doi: 10.1259/bjr.20201034. Online ahead of print. PMID: 33112652

Serogroup B meningococcal vaccination practice patterns on college campuses.
Haimowitz R, Torres R, Caleb S, Thompson D, Smith A, Ciotoli C, Dannenbaum M, Fu LY. Vaccine. 2020 Oct 27;38(46):7350-7356. doi: 10.1016/j.vaccine.2020.09.035. Epub 2020 Oct 1. PMID: 33010977

Immunotherapy in prostate cancer: new horizon of hurdles and hopes.
Tsaur I, Brandt MP, Juengel E, Manceau C, Ploussard G. World J Urol. 2020 Oct 26. doi: 10.1007/s00345-020-03497-1. Online ahead of print. PMID: 33106940

Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B **Vaccine**: Results of a Phase 3 randomized clinical trial in the Russian Federation.
Esaulenko EV, Yakovlev AA, Volkov GA, Sukhoruk AA, Surkov KG, Kruglyakov PV, Diaz-Mitoma F. Clin Infect Dis. 2020 Oct 29:ciaa1649. doi: 10.1093/cid/ciaa1649. Online ahead of print. PMID: 33119068

PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein **vaccine** and elicits regression of tumor in a preclinical model.
Peng S, Tan M, Li YD, Cheng MA, Farmer E, Ferrall L, Gaillard S, Roden RBS, Hung CF, Wu TC. Cancer Immunol Immunother. 2020 Oct 27. doi: 10.1007/s00262-020-02754-x. Online ahead of print. PMID: 33108473

DDX3 DEAD-box RNA helicase (Hel67) gene disruption impairs infectivity of Leishmania donovani and induces protective immunity against visceral leishmaniasis.
Pandey SC, Pande V, Samant M. Sci Rep. 2020 Oct 26;10(1):18218. doi: 10.1038/s41598-020-75420-y. PMID: 33106577 Free PMC article.

COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases.
Ratcliffe NA, Castro HC, Paixão IC, Mello CB. Curr Med Chem. 2020 Oct 27. doi: 10.2174/0929867327666201027152400. Online ahead of print. PMID: 33109030

FIGO Statement: Vaccination in pregnancy.
Nassar AH, Visser GHA, Nicholson WK, Ramasauskaite D, Kim YH, Barnea ER; FIGO Safe Motherhood, Newborn Health Committee. Int J Gynaecol Obstet. 2020 Oct 30. doi: 10.1002/ijgo.13456. Online ahead of print. PMID: 33128249

Polyethyleneimine-CpG Nanocomplex as an In Situ **Vaccine** for Boosting Anticancer Immunity in Melanoma.
Xu Y, Ma S, Si X, Zhao J, Yu H, Ma L, Song W, Tang Z. Macromol Biosci. 2020 Oct 26:e2000207. doi: 10.1002/mabi.202000207. Online ahead of print. PMID: 33107202

Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens.

Dobaño C, Vidal M, Santano R, Jiménez A, Chi J, Barrios D, Ruiz-Olalla G, Rodrigo Melero N, Carolis C, Parras D, Serra P, Martínez de Aguirre P, Carmona-Torre F, Reina G, Santamaria P, Mayor A, García-Basteiro A, Izquierdo L, Aguilar R, Moncunill G. J Clin Microbiol. 2020 Oct 30:JCM.01731-20. doi: 10.1128/JCM.01731-20. Online ahead of print. PMID: 33127841

Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses.
Hensel J, McAndrews KM, McGrail DJ, Dowlatshahi DP, LeBleu VS, Kalluri R. Sci Rep. 2020 Oct 27;10(1):18377. doi: 10.1038/s41598-020-75491-x. PMID: 33110184

Structure basis of non-structural protein pA151R from African Swine Fever Virus.
Huang JW, Niu D, Liu K, Wang Q, Ma L, Chen CC, Zhang L, Liu W, Zhou S, Min J, Wu S, Yang Y, Guo RT. Biochem Biophys Res Commun. 2020 Oct 29;532(1):108-113. doi: 10.1016/j.bbrc.2020.08.011. Epub 2020 Aug 20. PMID: 32828542

Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness.
Chen PL, Tzeng TT, Hu AY, Wang LH, Lee MS. Vaccines (Basel). 2020 Oct 25;8(4):E626. doi: 10.3390/vaccines8040626. PMID: 33113866

Planning and implementing a targeted polio vaccination campaign for Somali mobile populations in Northeastern Kenya based on migration and settlement patterns.
Harvey B, Dalal W, Amin F, McIntyre E, Ward S, Merrill RD, Mohamed A, Hsu CH. Ethn Health. 2020 Oct 30:1-16. doi: 10.1080/13557858.2020.1838455. Online ahead of print. PMID: 33126830

Immune duration of a recombinant PRRSV **vaccine** expressing E2 of CSFV.
Gao F, Jiang Y, Li G, Zhang Y, Zhao K, Zhu H, Li L, Yu L, Zheng H, Zhou Y, Tong W, Tong G. Vaccine. 2020 Oct 29:S0264-410X(20)31366-9. doi: 10.1016/j.vaccine.2020.10.057. Online ahead of print. PMID: 33131934

Are patients with inflammatory bowel disease receiving adequate immunisation?
Quera R, Simian D, Núñez P, Flores L, Figueroa C, Ibáñez P, Kronberg U, Lubascher J, Pizarro G. Gastroenterol Hepatol. 2020 Oct 29:S0210-5705(20)30303-4. doi: 10.1016/j.gastrohep.2020.06.024. Online ahead of print. PMID: 33131901

Monitoring influenza vaccination coverage and acceptance among health-care workers in German hospitals - results from three seasons.
Neufeind J, Wenchel R, Boedeker B, Wicker S, Wichmann O. Hum Vaccin Immunother. 2020 Oct 30:1-9. doi: 10.1080/21645515.2020.1801072. Online ahead of print. PMID: 33124954

Mechanisms and potential therapeutic targets of hyperinflammatory responses in SARS-CoV2.
Chukwuma IF, Apeh VO, C OF. Acta Virol. 2020 Oct 28. doi: 10.4149/av_2021_102. Online ahead of print. PMID: 33112637

Immunoliposomes bearing lymphocyte activation gene 3 fusion protein (LAG3-Ig) and P5 HER2/neu-derived peptide: a novel **vaccine** for breast cancer.

Mohammadian Haftcheshmeh S, Zamani P, Mashreghi M, Nikpoor AR, Tavakkol-Afshari J, Jaafari MR. Biotechnol Prog. 2020 Oct 29:e3095. doi: 10.1002/btpr.3095. Online ahead of print. PMID: 33118322

Total Synthesis and Immunological Evaluation of the Tri-d-glycero-d-manno-heptose Antigen of the Lipopolysaccharide as a **Vaccine** Candidate against Helicobacter pylori.
Wang J, Zhang Y, Zhu Y, Liu J, Chen Y, Cao X, Yang Y. Org Lett. 2020 Oct 29. doi: 10.1021/acs.orglett.0c03105. Online ahead of print. PMID: 33119312

Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older.
Wolfe DN, Espeland EM, Gao Y, Lu D, Blatner G, Amass K, Horwith G, Tong XM, Hopkins R, David GL, Jepson BM, King JC Jr. Vaccine. 2020 Oct 28:S0264-410X(20)31362-1. doi: 10.1016/j.vaccine.2020.10.053. Online ahead of print. PMID: 33129609

DAR-901 **vaccine** for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial.
Munseri P, Said J, Amour M, Magohe A, Matee M, Rees CA, Mackenzie T, Tvaroha S, Bailey-Kellogg C, Maro I, Wieland-Alter W, Adams LV, Horsburgh CR, Nakamura K, Arbeit RD, Pallangyo K, von Reyn CF. Vaccine. 2020 Oct 27;38(46):7239-7245. doi: 10.1016/j.vaccine.2020.09.055. Epub 2020 Sep 29. PMID: 33004239

The impact of oxidative stress damage induced by the environmental stressors on COVID-19.
Bakadia BM, Boni BOO, Ahmed AAQ, Yang G. Life Sci. 2020 Oct 26:118653. doi: 10.1016/j.lfs.2020.118653. Online ahead of print. PMID: 33115606

Full-dose hepatitis B virus vaccination coverage and associated factors among health care workers in Ethiopia: A systematic review and meta-analysis.
Awoke N, Mulgeta H, Lolaso T, Tekalign T, Samuel S, Obsa MS, Olana R. PLoS One. 2020 Oct 27;15(10):e0241226. doi: 10.1371/journal.pone.0241226. eCollection 2020. PMID: 33108365

Chemical synthesis and antigenic activity of a phosphatidylinositol mannoside epitope from *Mycobacterium tuberculosis*.
Zhao SY, Li N, Luo WY, Zhang NN, Zhou RY, Li CY, Wang J. Chem Commun (Camb). 2020 Oct 26. doi: 10.1039/d0cc05573e. Online ahead of print. PMID: 33104149

The Contribution of Extrachromosomal DNA to Genome Plasticity in Malaria Parasites.
Zhang X, Deitsch KW, Kirkman LA. Mol Microbiol. 2020 Oct 26. doi: 10.1111/mmi.14632. Online ahead of print. PMID: 33103309

Control of Brucella melitensis in endemic settings: a simulation study in the Nile Delta, Egypt.
Mohammed Hegazy Y, Schley D, Ridler A, Beauvais W, Musallam I, Guitian J. Transbound Emerg Dis. 2020 Oct 28. doi: 10.1111/tbed.13897. Online ahead of print. PMID: 33118284

A novel synthetic DNA **vaccine** elicits protective immune responses against Powassan virus.
Choi H, Kudchodkar SB, Ho M, Reuschel EL, Reynolds E, Xu Z, Bordoloi D, Ugen KE, Tebas P, Kim J, Abdel-Mohsen M, Thangamani S, Weiner DB, Muthumani K. PLoS Negl Trop Dis. 2020 Oct 29;14(10):e0008788. doi: 10.1371/journal.pntd.0008788. eCollection 2020 Oct. PMID: 33119599

Adapting Center for Disease Control and Prevention's immunization quality improvement program to improve maternal vaccination uptake in obstetrics.
Spina CI, Brewer SE, Ellingson MK, Chamberlain AT, Limaye RJ, Orenstein WA, Salmon DA, Omer SB, O'Leary ST. Vaccine. 2020 Oct 26:S0264-410X(20)31360-8. doi: 10.1016/j.vaccine.2020.10.051. Online ahead of print. PMID: 33121843

Viral Subpopulation Screening Guides in Designing a High Interferon Inducing Live Attenuated Influenza **Vaccine** by Targeting Rare Mutations in NS1 and PB2 Proteins.
Ghorbani A, Abundo MC, Ji H, Taylor KJM, Ngunjiri JM, Lee CW. J Virol. 2020 Oct 28:JVI.01722-20. doi: 10.1128/JVI.01722-20. Online ahead of print. PMID: 33115873

Improving the quality and use of immunization and surveillance data: Summary report of the Working Group of the Strategic Advisory Group of Experts on Immunization.
Scobie HM, Edelstein M, Nicol E, Morice A, Rahimi N, MacDonald NE, Carolina Danovaro-Holliday M, Jawad J; SAGE Working Group on Immunization and Surveillance Data Quality and Use. Vaccine. 2020 Oct 27;38(46):7183-7197. doi: 10.1016/j.vaccine.2020.09.017. Epub 2020 Sep 17. PMID: 32950304

Ensemble forecast modeling for the design of COVID-19 **vaccine** efficacy trials.
Dean NE, Pastore Y Piontti A, Madewell ZJ, Cummings DAT, Hitchings MDT, Joshi K, Kahn R, Vespignani A, Halloran ME, Longini IM Jr. Vaccine. 2020 Oct 27;38(46):7213-7216. doi: 10.1016/j.vaccine.2020.09.031. Epub 2020 Sep 15. PMID: 33012602

A pilot study on use of live attenuated rotavirus **vaccine** (Rotarix) as an infection challenge model.
Chilengi R, Simuyandi M, Chibuye M, Chirwa M, Sukwa N, Laban N, Chisenga C, Silwamba S, Grassly N, Bosomprah S. Vaccine. 2020 Oct 27;38(46):7357-7362. doi: 10.1016/j.vaccine.2020.09.023. Epub 2020 Oct 5. PMID: 33032844

Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate **vaccine** in the national immunisation programme in the UK.
Ladhani SN, Andrews N, Ramsay ME. Lancet Infect Dis. 2020 Oct 29:S1473-3099(20)30492-8. doi: 10.1016/S1473-3099(20)30492-8. Online ahead of print. PMID: 33129426

High Rate of Circulating MERS-CoV in Dromedary Camels at Slaughterhouses in Riyadh, 2019.
Aljasim TA, Almasoud A, Aljami HA, Alenazi MW, Alsagaby SA, Alsaleh AN, Alharbi NK. Viruses. 2020 Oct 27;12(11):E1215. doi: 10.3390/v12111215. PMID: 33120981

Multiple gene targeting siRNAs for down regulation of Immediate Early-2 (Ie2) and DNA polymerase genes mediated inhibition of novel rat Cytomegalovirus (strain All-03).

Balakrishnan KN, Abdullah AA, Bala JA, Jesse FFA, Abdullah CAC, Noordin MM, Mohd-Azmi ML. Virol J. 2020 Oct 27;17(1):164. doi: 10.1186/s12985-020-01436-5. PMID: 33109247

On the relationship between BCG coverage and national Covid-19 outcome: could "heterologous" herd immunity explain why some countries are better off?
Lerm M. J Intern Med. 2020 Oct 27. doi: 10.1111/joim.13198. Online ahead of print. PMID: 33107999

Protection of chicks from Newcastle disease by combined vaccination with a plasmid DNA and the pre-fusion protein of the virulent genotype VII of Newcastle disease virus.
Sun J, Han Z, Zhao R, Ai H, Chen L, Li L, Liu S. Vaccine. 2020 Oct 27;38(46):7337-7349. doi: 10.1016/j.vaccine.2020.09.039. Epub 2020 Sep 25. PMID: 32981778

Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1.
Skansberg A, Sauer M, Tan M, Santosham M, Jennings MC. Hum Vaccin Immunother. 2020 Oct 29:1-12. doi: 10.1080/21645515.2020.1804245. Online ahead of print. PMID: 33121329

Analysis of individual strategies for artificial and natural immunity with imperfectness and durability of protection.
Ariful Kabir KM, Tanimoto J. J Theor Biol. 2020 Oct 28:110531. doi: 10.1016/j.jtbi.2020.110531. Online ahead of print. PMID: 33129951

Community engagement strategy for increased uptake of routine immunization and select perinatal services in north-west Ethiopia: A descriptive analysis.
Demissie SD, Kozuki N, Olorunsaiye CZ, Gebrekirstos P, Mohammed S, Kiapi L, Chantler T, Karafillakis E, Landegger J. PLoS One. 2020 Oct 29;15(10):e0237319. doi: 10.1371/journal.pone.0237319. eCollection 2020. PMID: 33119604

Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges.
Reneer ZB, Jamieson PJ, Skarlupka AL, Huang Y, Ross TM. J Virol. 2020 Oct 28:JVI.01526-20. doi: 10.1128/JVI.01526-20. Online ahead of print. PMID: 33115871

COVID-19: a user's guide, status of the art, and an original proposal to terminate viral recurrence.
Actis GC, Ribaldone DG, Fagoonee S, Pellicano R. Minerva Med. 2020 Oct 26. doi: 10.23736/S0026-4806.20.07054-8. Online ahead of print. PMID: 33104300

Intention to Vaccinate Against the Novel 2019 Coronavirus Disease: The Role of Health Locus of Control and Religiosity.
Olagoke AA, Olagoke OO, Hughes AM. J Relig Health. 2020 Oct 30:1-16. doi: 10.1007/s10943-020-01090-9. Online ahead of print. PMID: 33125543

Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 **Vaccine** Approval.
Avorn J, Kesselheim AS. N Engl J Med. 2020 Oct 29;383(18):1706-1708. doi: 10.1056/NEJMp2029479. Epub 2020 Sep 15. PMID: 32931162

Prediction of probability of rubella based on eye outcomes (PORBEO Nomogram)-a cross-sectional sentinel surveillance of 1134 infants.
Gupta PC, Kumar-M P, Ram J, Verma S, Sachdeva RK, Singh K, Bavdekar A, Shah S, Sangappa M, Murthy KR, Santhanam S, John D, Shanmugasundaram D, Sabrinathan R, Murhekar M. Graefes Arch Clin Exp Ophthalmol. 2020 Oct 29. doi: 10.1007/s00417-020-04973-5. Online ahead of print. PMID: 33119803

Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.
Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M, Saavedra MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G, Nguyen HAT, Long JH, Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS, Chou CW, Javanmardi K, Finkelstein IJ, Musser JM. mBio. 2020 Oct 30;11(6):e02707-20. doi: 10.1128/mBio.02707-20. PMID: 33127862

The respiratory syncytial virus fusion protein-specific B cell receptor repertoire reshaped by post-fusion subunit vaccination.
Schneikart G, Tavarini S, Sammicheli C, Torricelli G, Guidotti S, Andreano E, Buricchi F, D'Oro U, Finco O, Bardelli M. Vaccine. 2020 Oct 29:S0264-410X(20)31371-2. doi: 10.1016/j.vaccine.2020.10.062. Online ahead of print. PMID: 33131932

Capture-based enrichment of Theileria parva DNA enables full genome assembly of first buffalo-derived strain and reveals exceptional intra-specific genetic diversity.
Palmateer NC, Tretina K, Orvis J, Ifeonu OO, Crabtree J, Drabék E, Pelle R, Awino E, Gotia HT, Munro JB, Tallon L, Morrison WI, Daubenberger CA, Nene V, Knowles DP, Bishop RP, Silva JC. PLoS Negl Trop Dis. 2020 Oct 29;14(10):e0008781. doi: 10.1371/journal.pntd.0008781. Online ahead of print. PMID: 33119590

Enhancement of HIV-1 Env-specific CD8 T cell responses using IFN-Stimulated Gene 15 (ISG15) as an immune adjuvant.
Elena Gómez C, Perdiguero B, Falqui M, Quirós M, Bécares M, Sorzano CÓS, García-Arriaza J, Esteban M, Guerra S. J Virol. 2020 Oct 28:JVI.01155-20. doi: 10.1128/JVI.01155-20. Online ahead of print. PMID: 33115866

Quantum Chemical and Molecular Dynamics Studies of MUC1 Calix[4,8]arene Scaffold Based Anticancer **Vaccine** Candidates.
Spadaro A, Basile L, Pappalardo M, Bonaccorso C, Rao M, Ronsisvalle S, Granata G, Guccione S. J Chem Inf Model. 2020 Oct 26;60(10):5162-5171. doi: 10.1021/acs.jcim.9b00989. Epub 2020 Aug 31. PMID: 32818373

One year period of invasive pneumococcal disease in children from a tertiary care hospital in Turkey in the post-**vaccine** era.
Ustundag G, Karadag-Oncel E, Sen-Tas S, Kara-Aksay A, Yilmaz-Ciftdogan D, Yilmaz N, Ceyhan M. Hum Vaccin Immunother. 2020 Oct 29:1-4. doi: 10.1080/21645515.2020.1817716. Online ahead of print. PMID: 33121316

Comparative study of intralesional tuberculin protein purified derivative (PPD) and intralesional measles, mumps, rubella (MMR) **vaccine** for multiple resistant warts.

Mohammed YF, Ibrahim HS, Elbarbary MA, Elsaie ML. J Cosmet Dermatol. 2020 Oct 29. doi: 10.1111/jocd.13634. Online ahead of print. PMID: 33118675

Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations.
Ghorbani M, Brooks BR, Klauda JB. J Phys Chem B. 2020 Oct 28. doi: 10.1021/acs.jpcb.0c05994. Online ahead of print. PMID: 33112147

Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets.
Xu C, Hong H, Lee Y, Park KS, Sun M, Wang T, Aikins ME, Xu Y, Moon JJ. ACS Nano. 2020 Oct 27;14(10):13268-13278. doi: 10.1021/acsnano.0c05062. Epub 2020 Sep 15. PMID: 32902245

Production of fever mediator $PGE_2$ in human monocytes activated with MDP adjuvant is controlled by signaling from MAPK and p300 HAT: Key role of T cell derived factor.
Liu F, Romantseva T, Park YJ, Golding H, Zaitseva M. Mol Immunol. 2020 Oct 27;128:139-149. doi: 10.1016/j.molimm.2020.10.008. Online ahead of print. PMID: 33126082

Deciphering the Structural Enigma of HLA Class-II Binding Peptides for Enhanced Immunoinformatics-based Prediction of **Vaccine** Epitopes.
Chatterjee D, Priyadarshini P, Das DK, Mushtaq K, Singh B, Agrewala JN. J Proteome Res. 2020 Oct 26. doi: 10.1021/acs.jproteome.0c00405. Online ahead of print. PMID: 33103906

Hepatitis A person-to-person outbreaks: Epidemiology, morbidity burden, and factors associated with hospitalization - Multiple States, 2016-2019.
Hofmeister MG, Xing J, Foster MA, Augustine RJ, Burkholder C, Collins J, McBee S, Thomasson ED, Thoroughman D, Weng MK, Spradling PR. J Infect Dis. 2020 Oct 24:jiaa636. doi: 10.1093/infdis/jiaa636. Online ahead of print. PMID: 33097935

Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.
M P, Reddy GJ, Hema K, Dodoala S, Koganti B. Eur J Pharmacol. 2020 Oct 29:173688. doi: 10.1016/j.ejphar.2020.173688. Online ahead of print. PMID: 33130280

Opportunistic influenza vaccination in the home: broadening access in isolated times.
Nisbet LC, Cobbledick AM, Smith TE, Bryant PA, Lawrence J. Arch Dis Child. 2020 Oct 27:archdischild-2020-320273. doi: 10.1136/archdischild-2020-320273. Online ahead of print. PMID: 33109521

Metabolic defects in splenic B cell compartments from patients with liver cirrhosis.
Huang M, Liu X, Ye H, Zhao X, Zhao J, Liu Y, He X, Qu M, Pan J, Hou B, Cheng Y, Liu Z, Li Z, Liu L, Sun J, Zhang S, Zhang Z. Cell Death Dis. 2020 Oct 24;11(10):915. doi: 10.1038/s41419-020-03060-1. PMID: 33099582

Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors.
Jang GY, Kim YS, Lee SE, Lee JW, Han HD, Kang TH, Park YM. Cancer Immunol Immunother. 2020 Oct 28. doi: 10.1007/s00262-020-02759-6. Online ahead of print. PMID: 33113002

TMEM16A/ANO1 calcium-activated chloride channel as a novel target for the treatment of human respiratory syncytial virus infection.
Pearson H, Todd EJAA, Ahrends M, Hover SE, Whitehouse A, Stacey M, Lippiat JD, Wilkens L, Fieguth HG, Danov O, Hesse C, Barr JN, Mankouri J. Thorax. 2020 Oct 27:thoraxjnl-2020-215171. doi: 10.1136/thoraxjnl-2020-215171. Online ahead of print. PMID: 33109690

Evaluation of patients with primary immunodeficiency associated with Bacille Calmette-Guerin (BCG)-**vaccine**-derived complications.
Sohani M, Habibi S, Delavari S, Shahkarami S, Yazdani R, Shirmast P, Nazari F, Shad TM, Mamishi S, Azizi G, Anka AU, Hassanpour G, Kalantari A, Shariat M, Shafiei A, Abolhassani H, Aghamohammadi A. Allergol Immunopathol (Madr). 2020 Oct 25:S0301-0546(20)30112-9. doi: 10.1016/j.aller.2020.04.004. Online ahead of print. PMID: 33115608

Role of Tryptophan Residues in the Toxicity and Photosensitized Inactivation of *Escherichia coli* α-Hemolysin.
Reid LO, Thomas AH, Herlax V, Dántola ML. Biochemistry. 2020 Oct 27. doi: 10.1021/acs.biochem.0c00660. Online ahead of print. PMID: 33108867

The views of ethnic minority and vulnerable communities towards participation in COVID-19 **vaccine** trials.
Ekezie W, Czyznikowska BM, Rohit S, Harrison J, Miah N, Campbell-Morris P, Khunti K. J Public Health (Oxf). 2020 Oct 30:fdaa196. doi: 10.1093/pubmed/fdaa196. Online ahead of print. PMID: 33124667

Missed **Vaccine** Opportunities to S. pneumoniae and Influenza in Patients Admitted During the COVID-19 Pandemic.
Shallal A, Kenney R, Weinmann A. Infect Control Hosp Epidemiol. 2020 Oct 26:1-8. doi: 10.1017/ice.2020.1294. Online ahead of print. PMID: 33100230

Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Nanogel as a Pro-Antigen Strategy with Enhanced Protective Immune Responses.
Chen L, Liu B, Sun P, Wang W, Luo S, Zhang W, Yang Y, Wang Z, Lin J, Chen PR. Small. 2020 Oct 26:e2004237. doi: 10.1002/smll.202004237. Online ahead of print. PMID: 33107685

Molecular architecture and domain arrangement of the placental malaria protein VAR2CSA suggests a model for carbohydrate binding.
Bewley MC, Gautam L, Jagadeeshaprasad MG, Gowda DC, Flanagan JM. J Biol Chem. 2020 Oct 29:jbc.RA120.014676. doi: 10.1074/jbc.RA120.014676. Online ahead of print. PMID: 33122198

Pertussis in Italy: how to protect the "unprotectable"?
Fiasca F, Necozione S, Mattei A. Hum Vaccin Immunother. 2020 Oct 29:1-6. doi: 10.1080/21645515.2020.1806673. Online ahead of print. PMID: 33121322

Understanding host immune responses to pneumococcal proteins in the upper respiratory tract to develop serotype-independent pneumococcal vaccines.
Lagousi T, Basdeki P, De Jonge MI, Spoulou V. Expert Rev Vaccines. 2020 Oct 27. doi: 10.1080/14760584.2020.1843433. Online ahead of print. PMID: 33107359

DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model.
Dias RS, Teixeira MD, Xisto MF, Prates JWO, Silva JDD, Mello IO, Silva CCD, De Paula SO. Hum Vaccin Immunother. 2020 Oct 29:1-7. doi: 10.1080/21645515.2020.1826798. Online ahead of print. PMID: 33121347

Machine learning model demonstrates stunting at birth and systemic inflammatory biomarkers as predictors of subsequent infant growth - a four-year prospective study.
Harrison E, Syed S, Ehsan L, Iqbal NT, Sadiq K, Umrani F, Ahmed S, Rahman N, Jakhro S, Ma JZ, Hughes M, Ali SA. BMC Pediatr. 2020 Oct 30;20(1):498. doi: 10.1186/s12887-020-02392-3. PMID: 33126871

A parainfluenza virus vector expressing the respiratory syncytial virus (RSV) prefusion F protein is more effective than RSV for boosting a primary immunization with RSV.
Liang B, Matsuoka Y, Le Nouën C, Liu X, Herbert R, Swerczek J, Santos C, Paneru M, Collins PL, Buchholz UJ, Munir S. J Virol. 2020 Oct 28:JVI.01512-20. doi: 10.1128/JVI.01512-20. Online ahead of print. PMID: 33115876

A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus.
Vergara C, Valencia A, Thio CL, Goedert JJ, Mangia A, Piazzolla V, Johnson E, Kral AH, O'Brien TR, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Wojcik GL, Taub MA, Thomas DL, Duggal P. J Infect Dis. 2020 Oct 29:jiaa677. doi: 10.1093/infdis/jiaa677. Online ahead of print. PMID: 33119750

Epidemiology of Japanese Encephalitis in the Philippines prior to routine immunization.
Lopez AL, Raguindin PF, Aldaba JG, Avelino F, Sy AK, Heffelfinger JD, Silva MWT. Int J Infect Dis. 2020 Oct 27:S1201-9712(20)32265-7. doi: 10.1016/j.ijid.2020.10.061. Online ahead of print. PMID: 33127505

"Trained immunity" from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes.
Singh S, Maurya RP, Singh RK. PLoS Pathog. 2020 Oct 29;16(10):e1008969. doi: 10.1371/journal.ppat.1008969. eCollection 2020 Oct. PMID: 33119725

The Brazilian National Immunization Program: 46 years of achievements and challenges.
Domingues CMAS, Maranhão AGK, Teixeira AM, Fantinato FFS, Domingues RAS. Cad Saude Publica. 2020 Oct 26;36Suppl 2(Suppl 2):e00222919. doi: 10.1590/0102-311X00222919. eCollection 2020. PMID: 33111749

Analysis of humoral immune responses in SARS-CoV-2 infected patients.
Henss L, Scholz T, von Rhein C, Wieters I, Borgans F, Eberhardt FJ, Zacharowski K, Ciesek S, Rohde G, Vehreschild M, Stephan C, Wolf T, Hofmann-Winkler H, Scheiblauer H, Schnierle BS. J Infect Dis. 2020 Oct 31:jiaa680. doi: 10.1093/infdis/jiaa680. Online ahead of print. PMID: 33128369

The Health Belief Model in predicting healthcare workers' intention for influenza **vaccine** uptake in Jordan.
Alhalaseh L, Fayoumi H, Khalil B. Vaccine. 2020 Oct 27;38(46):7372-7378. doi: 10.1016/j.vaccine.2020.09.002. Epub 2020 Sep 16. PMID: 32950300

SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.
Huang WC, Zhou S, He X, Chiem K, Mabrouk MT, Nissly RH, Bird IM, Strauss M, Sambhara S, Ortega J, Wohlfert EA, Martinez-Sobrido L, Kuchipudi SV, Davidson BA, Lovell JF. Adv Mater. 2020 Oct 28:e2005637. doi: 10.1002/adma.202005637. Online ahead of print. PMID: 33111375

The UK Government's **Vaccine** Taskforce: strategy for protecting the UK and the world.
Bingham K. Lancet. 2020 Oct 27:S0140-6736(20)32175-9. doi: 10.1016/S0140-6736(20)32175-9. Online ahead of print. PMID: 33125932

Different Long-Term Duration of Seroprotection against *Neisseria meningitidis* in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands.
Ohm M, van Rooijen DM, Bonačić Marinović AA, van Ravenhorst MB, van der Heiden M, Buisman AM, Sanders EAM, Berbers GAM. Vaccines (Basel). 2020 Oct 25;8(4):E624. doi: 10.3390/vaccines8040624. PMID: 33113834

Decontamination of SARS-CoV-2 and Other RNA Viruses from N95 Level Meltblown Polypropylene Fabric Using Heat under Different Humidities.
Campos RK, Jin J, Rafael GH, Zhao M, Liao L, Simmons G, Chu S, Weaver SC, Chiu W, Cui Y. ACS Nano. 2020 Oct 27;14(10):14017-14025. doi: 10.1021/acsnano.0c06565. Epub 2020 Sep 29. PMID: 32955847

Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus **vaccine** switch in 2016.
Ahmad M, Verma H, Kunwar A, Soni S, Sinha U, Gawande M, Sethi R, Nalavade U, Sharma D, Bhatnagar P, Bahl S, Deshpande J. Int J Infect Dis. 2020 Oct 29:S1201-9712(20)32282-7. doi: 10.1016/j.ijid.2020.10.078. Online ahead of print. PMID: 33130206

Herd Protection against Meningococcal Disease through Vaccination.
Clark SA, Borrow R. Microorganisms. 2020 Oct 28;8(11):E1675. doi: 10.3390/microorganisms8111675. PMID: 33126756

Nurses' experiences of their decision-making process when participating in clinical trials during the 2014-2016 West African Ebola crisis.
Nguyen D, Arnaert A, Pringle J, Ponzoni N, Kouyaté S, Fansia N, Nouvet E. Public Health Nurs. 2020 Oct 27. doi: 10.1111/phn.12822. Online ahead of print. PMID: 33111332

Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018 - 2019 outbreak.
Bassal R, Indenbaum V, Pando R, Levin T, Shinar E, Amichay D, Barak M, Ben-Dor A, Haim AB, Mendelson E, Cohen D, Shohat T. Hum Vaccin Immunother. 2020 Oct 29:1-5. doi: 10.1080/21645515.2020.1824968. Online ahead of print. PMID: 33121333

The estimated impact of decreased childhood vaccination due to COVID-19 using a dynamic transmission model of mumps in Japan.
Kitano T, Aoki H. Hum Vaccin Immunother. 2020 Oct 29:1-4. doi: 10.1080/21645515.2020.1826799. Online ahead of print. PMID: 33121326

The Association between Influenza Vaccination and the Risk of SARS-CoV-2 Infection, Severe Illness, and Death: A Systematic Review of the Literature.
Del Riccio M, Lorini C, Bonaccorsi G, Paget J, Caini S. Int J Environ Res Public Health. 2020 Oct 27;17(21):E7870. doi: 10.3390/ijerph17217870. PMID: 33121070

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X, Drelich A, Li W, Chen C, Sun Z, Shi M, Adams C, Mellors JW, Tseng CT, Dimitrov DS. Vaccine. 2020 Oct 27;38(46):7205-7212. doi: 10.1016/j.vaccine.2020.09.058. Epub 2020 Sep 22. PMID: 33010978

New polio **vaccine** poised to get emergency WHO approval.
Irwin A. Nature. 2020 Oct 29. doi: 10.1038/d41586-020-03045-2. Online ahead of print. PMID: 33122836

Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity.
Eichinger KM, Kosanovich JL, Lipp MA, Perkins TN, Petrovsky N, Marshall C, Yondola MA, Empey KM. Vaccine. 2020 Oct 28:S0264-410X(20)31374-8. doi: 10.1016/j.vaccine.2020.10.065. Online ahead of print. PMID: 33129608

COVID-19 **vaccine** race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.
Campillo NE, Jimenez M, Canelles M. Curr Med Chem. 2020 Oct 27. doi: 10.2174/0929867327666201027153123. Online ahead of print. PMID: 33109026

Navigating country decisions in response to a global rotavirus **vaccine** shortage.
Jennings MC, Manchester C, Sauer M. Vaccine. 2020 Oct 27;38(46):7201-7204. doi: 10.1016/j.vaccine.2020.08.076. Epub 2020 Sep 18. PMID: 32958336

Masking terminal neo-epitopes of linear peptides through glycosylation favours immune responses towards core epitopes producing parental protein bound antibodies.
Pon R, Marcil A, Chen W, Gadoury C, Williams D, Chan K, Zhou H, Ponce A, Paquet E, Gurnani K, Chattopadhyay A, Zou W. Sci Rep. 2020 Oct 28;10(1):18497. doi: 10.1038/s41598-020-75754-7. PMID: 33116268

Effectiveness of Chemical Compounds Used against African Swine Fever Virus in Commercial Available Disinfectants.
Juszkiewicz M, Walczak M, Mazur-Panasiuk N, Woźniakowski G. Pathogens. 2020 Oct 24;9(11):E878. doi: 10.3390/pathogens9110878. PMID: 33114391

Koalas vaccinated against Koala retrovirus respond by producing increased levels of interferon-gamma.
Olagoke O, Quigley BL, Timms P. Virol J. 2020 Oct 31;17(1):168. doi: 10.1186/s12985-020-01442-7. PMID: 33129323

The relationship between rates of hospitalization for ambulatory care sensitive conditions and local access to primary healthcare in Manitoba First Nations communities : Results from the Innovation in Community-based Primary Healthcare Supporting Transformation in the Health of First Nations in Manitoba (iPHIT) study.
Lavoie JG, Philips-Beck W, Kinew KA, Kyoon-Achan G, Sinclair S, Katz A. Can J Public Health. 2020 Oct 30. doi: 10.17269/s41997-020-00421-3. Online ahead of print. PMID: 33125638

The impact of export regulations on recombinant viral **vaccine** development for emerging infectious diseases.
Wolf J, Hansen R, Hassis K, Lapps W, Warmuth E. Vaccine. 2020 Oct 27;38(46):7198-7200. doi: 10.1016/j.vaccine.2020.09.057. Epub 2020 Oct 5. PMID: 33032845

Dendritic Mesoporous Silica Nanoparticle Adjuvants Modified with Binuclear Aluminum Complex: Coordination Chemistry Dictates Adjuvanticity.
Yang Y, Tang J, Song H, Yang Y, Gu Z, Fu J, Liu Y, Zhang M, Qiao ZA, Yu C. Angew Chem Int Ed Engl. 2020 Oct 26;59(44):19610-19617. doi: 10.1002/anie.202006861. PMID: 32876984

A Retrospective Epidemiological Study of Tick-Borne Encephalitis Virus in Patients with Neurological Disorders in Hokkaido, Japan.
Yoshii K, Takahashi-Iwata I, Shirai S, Kobayashi S, Yabe I, Sasaki H. Microorganisms. 2020 Oct 28;8(11):E1672. doi: 10.3390/microorganisms8111672. PMID: 33126600

No-Fault Compensation for **Vaccine** Injury - The Other Side of Equitable Access to Covid-19 Vaccines.
Halabi S, Heinrich A, Omer SB. N Engl J Med. 2020 Oct 28. doi: 10.1056/NEJMp2030600. Online ahead of print. PMID: 33113309

Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?
Luyten J, Kessels R, Vandermeulen C, Beutels P. Vaccines (Basel). 2020 Oct 28;8(4):E628. doi: 10.3390/vaccines8040628. PMID: 33126454

BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Junqueira-Kipnis AP, Dos Anjos LRB, Barbosa LCS, da Costa AC, Borges KCM, Cardoso ADRO, Ribeiro KM, Rosa SBA, Souza CC, das Neves RC, Saraiva G, da Silva SM, da Silveira EA, Rabahi MF, Conte MB, Kipnis A. Trials. 2020 Oct 26;21(1):881. doi: 10.1186/s13063-020-04822-0. PMID: 33106170

Identifying individual predictive factors for treatment efficacy.
Alonso A, Van der Elst W, Sanchez L, Luaces P, Molenberghs G. Biometrics. 2020 Oct 30. doi: 10.1111/biom.13398. Online ahead of print. PMID: 33128231

Immunity after COVID-19: Protection or sensitization?
Danchin A, Turinici G. Math Biosci. 2020 Oct 28:108499. doi: 10.1016/j.mbs.2020.108499. Online ahead of print. PMID: 33129826

On-farm **vaccine** storage needs improvement.
[No authors listed] Vet Rec. 2020 Oct 31;187(9):346. doi: 10.1136/vr.m4202. PMID: 33127775

Reply to letter from Alvarez et al.
Ruiz-Aragón J, Gani R, Márquez S, Alvarez P. Hum Vaccin Immunother. 2020 Oct 29:1-2. doi: 10.1080/21645515.2020.1813485. Online ahead of print. PMID: 33121349

Modifying bacterial flagellin to evade Nod-like Receptor CARD 4 recognition enhances protective immunity against Salmonella.
Tourlomousis P, Wright JA, Bittante AS, Hopkins LJ, Webster SJ, Bryant OJ, Mastroeni P, Maskell DJ, Bryant CE. Nat Microbiol. 2020 Oct 26. doi: 10.1038/s41564-020-00801-y. Online ahead of print. PMID: 33106673

Synthesis of a pentasaccharide repeating unit of lipopolysaccharide derived from virulent E. coli O1 and identification of a glycotope candidate of avian pathogenetic E. coli O1.
Nishi N, Seki K, Takahashi D, Toshima K. Angew Chem Int Ed Engl. 2020 Oct 30. doi: 10.1002/anie.202013729. Online ahead of print. PMID: 33124093

Mesoporous silica nanoparticles containing silver as novel antimycobacterial agents against Mycobacterium tuberculosis.
Montalvo-Quirós S, Gómez-Graña S, Vallet-Regí M, Prados-Rosales RC, González B, Luque-Garcia JL. Colloids Surf B Biointerfaces. 2020 Oct 25;197:111405. doi: 10.1016/j.colsurfb.2020.111405. Online ahead of print. PMID: 33130523

Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 **vaccine** development.
Kahn JP, Henry LM, Mastroianni AC, Chen WH, Macklin R. Proc Natl Acad Sci U S A. 2020 Oct 29:202021189. doi: 10.1073/pnas.2021189117. Online ahead of print. PMID: 33122444

Host genetic variation explains reduced protection of commercial vaccines against Piscirickettsia salmonis in Atlantic salmon.
Figueroa C, Veloso P, Espin L, Dixon B, Torrealba D, Elalfy IS, Afonso JM, Soto C, Conejeros P, Gallardo JA. Sci Rep. 2020 Oct 26;10(1):18252. doi: 10.1038/s41598-020-70847-9. PMID: 33106499

Letter in Reply: Toward a COVID-19 **Vaccine** Strategy for Pemphigus Patients on Rituximab.
Waldman RA, Creed M, Sharp K, Adalsteinnson J, Imitola J, Durso T, Lu J. J Am Acad Dermatol. 2020 Oct 29:S0190-9622(20)32896-6. doi: 10.1016/j.jaad.2020.10.075. Online ahead of print. PMID: 33130180

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain.
González-Peris S, Campins M, García-García JJ, Díaz-Conradi Á, Domínguez Á, Ciruela P, de Sevilla MF, Hernández S, Muñoz-Almagro C, Izquierdo C, Codina G, Uriona S, Esteva C, Solé-Ribalta A, Soldevila N,

Planes AM, Martínez-Osorio J, Salleras L, Moraga-Llop F; Barcino Working Group. Enferm Infecc Microbiol Clin. 2020 Oct 29:S0213-005X(20)30291-3. doi: 10.1016/j.eimc.2020.08.022. Online ahead of print. PMID: 33131931

A clinical perspective of the U.S. anti-vaccination epidemic: Considering marginal costs and benefits, CDC best practices guidelines, free riders, and herd immunity.
Anderson MG, Ballinger EA, Benjamin D, Frenkel LD, Hinnant CW Jr, Zucker KW. Vaccine. 2020 Oct 28:S0264-410X(20)31388-8. doi: 10.1016/j.vaccine.2020.10.068. Online ahead of print. PMID: 33129607

Recombinant H7 hemagglutinin expressed in glycoengineered Pichia pastoris forms nanoparticles that protect mice from challenge with H7N9 influenza virus.
Liu B, Shi P, Wang T, Zhao Y, Lu S, Li X, Luo S, Chang S, Wang S, Sun P, Gong X, Gao Y, Wu J. Vaccine. 2020 Oct 29:S0264-410X(20)31370-0. doi: 10.1016/j.vaccine.2020.10.061. Online ahead of print. PMID: 33131935

Maintaining confidentiality of emerging results in COVID-19 **vaccine** trials is essential.
Krause PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM; WHO Ad Hoc Clinical Trial Expert Group. Lancet. 2020 Oct 27:S0140-6736(20)32259-5. doi: 10.1016/S0140-6736(20)32259-5. Online ahead of print. PMID: 33125926

# Patentes registradas en PatentScope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20201024:20201031 as the publication date*

*36 records*

1.WO/2020/215350AVIAN INFLUENZA AND FOWL ADENOVIRUS SEROTYPE-4 COMBINED GENETIC ENGINEERING SUBUNIT VACCINE AND PREPARATION METHOD THEREFOR
WO - 29.10.2020
Int.Class A61K 39/235 Appl.No PCT/CN2019/085075 Applicant ZHAOQING DAHUANONG BIOLOGY MEDICINE CO., LTD Inventor CHEN, Ruiai
The present invention relates to the technical field of veterinary biological products, and provides an avian influenza and fowl adenovirus serotype-4 combined genetic engineering subunit vaccine. The antigen in the vaccine is a fusion antigen. The fusion antigen contains: a) avian influenza virus HA protein; b) fowl adenovirus fiber2 protein; and c) a specific linker peptide between the avian influenza virus HA protein and the fowl adenovirus fiber2 protein. The amino acid sequence of the specific linker peptide is as shown in SEQ ID NO: 2 in the sequence list. The vaccine contains a fusion antigen, which can induce fowls to produce high-level specific antibodies to protect the fowls from infection with avian influenza and fowl adenovirus. Moreover, the present invention also provides a preparation method for the vaccine.

2.20200338127Th1 vaccination priming for active immunotherapy
US - 29.10.2020
Int.Class A61K 35/17 Appl.No 16928884 Applicant Mirror Biologics, Inc. Inventor Michael Har-Noy

  

The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.

3.WO/2020/215351IMMUNOPOTENTIATOR, PREPARATION METHOD THEREFOR, AVIAN INFLUENZA VACCINE AND USE THEREOF
WO - 29.10.2020
Int.Class A61K 39/39 Appl.No PCT/CN2019/085076 Applicant ZHAOQING DAHUANONG BIOLOGY MEDICINE CO., LTD Inventor CHEN, Ruiai
Disclosed is an immunopotentiator comprising a bursin pentapeptide and an astragalus polysaccharide, wherein the weight ratio of the bursin pentapeptide to the astragalus polysaccharide is 1:5 to 1:20. The immunopotentiator is simple to prepare and can improve the expression level of antibody titer for vaccine immunity. Also disclosed are a method for preparing the immunopotentiator, an avian influenza vaccine using the immunopotentiator and the application of the immunopotentiator in the avian influenza vaccine.

4.20200338182Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
US - 29.10.2020
Int.Class A61K 39/04 Appl.No 16921959 Applicant The Regents of the University of California Inventor Sarah Stanley

A vaccine against *Mycobacterium tuberculosis* (*M. tuberculosis*) formulated for intranasal administration, comprises a first vaccine component comprising one or more *M. tuberculosis, Mycobacterium vaccae* (*M. vaccae*) or *Mycobacteroium bovis* (*M. bovis*) antigens, and a second vaccine component comprising a Stimulator of Interferon Genes (STING) activator.

5.3727439A VACCINE TO PROTECT A PIG AGAINST ACTINOBACILLUS PLEUROPNEUMONIAE
EP - 28.10.2020
Int.Class A61K 39/102 Appl.No 18829815 Applicant INTERVET INT BV Inventor WITVLIET MAARTEN HENDRIK
The present invention pertains to a vaccine to protect a pig against an infection with *Actinobacillus pleuropneumoniae*, the vaccine comprising an RTX toxin of *Actinobacillus pleuropneumoniae* recombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier.

6.3727443VACCINES AGAINST HENDRA AND NIPAH VIRUS INFECTION
EP - 28.10.2020
Int.Class A61K 39/155 Appl.No 18836314 Applicant ZOETIS SERVICES LLC Inventor DOMINOWSKI PAUL JOSEPH
Disclosed is a method of protecting an animal in need thereof from Hendra or Nipah virus infection comprising administering to said animal a single dose of a vaccine, the vaccine comprising:an antigen component comprising a Hendra antigen or a Nipah antigen; and an adjuvant comprising oil, polycationic carrier and a CpG containing immunostimulatory oligonucleotide, wherein the vaccine is a W/O emulsion.

7.WO/2020/215301ATTENUATED AFRICAN SWINE FEVER VIRUS WITH DELETED GENE AND USE OF SAME AS VACCINE

WO - 29.10.2020
Int.Class C12N 7/01 Appl.No PCT/CN2019/084469 Applicant HARBIN VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES Inventor BU, Zhigao
Provided is an attenuated African swine fever virus, a gene of which has been deleted, which can be used as a vaccine, a vaccine thereof, and a construction method therefor. The construction method comprises using Chinese epidemic strain Pig/CN/HLJ/2018 of African swine fever, and deleting a virulence gene of the African swine fever virus by means of gene engineering technology, thereby obtaining viruses, which have undergone gene deletion, from which MGF360-505R has been deleted and both CD2V and MGF360-505R have been deleted.

8.WO/2020/218949METHOD FOR PREPARING A CONJUGATE HAEMOPHILUS B-TYPE VACCINE
WO - 29.10.2020
Int.Class A61K 39/102 Appl.No PCT/RU2020/050077 Applicant THE FEDERAL STATE UNITARY ENTERPRISE“THE SAINT-PETERSBURG SCIENTIFIC RESEARCH INSTITUTE OF VACCINES AND SERUMS AND THE ENTERPRISE FOR THE PRODUCTION OF BACTERIAL PREPARATIONS" OF FEDERAL MEDICAL AND BIOLOGIC AGENCY Inventor TRUKHIN, Viktor Pavlovich
The invention relates to medical microbiology and can be used for producing vaccine preparations. A method for preparing a conjugate Haemophilus B-type vaccine is proposed. The method comprises culturing Haemophilus influenzae B-type "GKPM-Obolensk" B-7884 strain in a liquid nutrient medium supplemented with ribose, inactivating the culture by heating to 55±5°C and maintaining at this temperature for 15±3 minutes, separating the biomass using a centrifuge and isolating polyribosylribitol phosphate (PRP) by precipitation with a 10% solution of cetyltrimethylammonium bromide (CTAB). The method further comprises the steps of concentration, purification, clarification, activation of PRP and mixing thereof with tetanus toxoid. The substance produced is then purified and sterilised, pharmaceutically acceptable excipients are added thereto, and it is dispensed and freeze-dried. The method provides for an increased yield of the target product.

9.3727440LIQUID VACCINES OF LIVE ENVELOPED VIRUSES
EP - 28.10.2020
Int.Class A61K 39/12 Appl.No 18829858 Applicant INTERVET INT BV Inventor VERMEIJ PAUL
The present invention describes a liquid vaccine composition of a live enveloped virus and a pharmaceutically acceptable carrier, whereby the carrier is a natural deep-eutectic solvent (NADES), and the vaccine has a water activity of less than about 0.8. The NADES provides a stabilisation of the sensitive virus for prolonged time and at ambient temperature. In general, the liquid vaccine compositions according to the invention, in different compositions for the various enveloped viruses, show remarkable capabilities of stabilisation. This overcomes the need for lyophilisation, a great economic benefit. Also the liquid nature of the vaccines facilitates administration to human or animal targets.

10.3727432INTRADERMAL COMBINATION VACCINE AGAINST MYCOPLASMA AND PORCINE CIRCOVIRUS
EP - 28.10.2020
Int.Class A61K 39/00 Appl.No 18833856 Applicant HIPRA SCIENT S L U Inventor MONTANE GIRALT JORDI
The present invention provides a combination vaccine comprising one or more antigens of *Mycoplasma hyopneumoniae*, one or more antigens of Porcine circovirus, and pharmaceutically acceptable excipients and/or carriers, for use in the prevention and/or treatment of porcine enzootic pneumonia and/or Porcine Circovirus-Associated Diseases (PCVAD) by administration of the vaccine into the dermis of livestock, wherein

the one or more antigens of porcine circovirus comprises the PCV2 ORF2 protein in an amount from 0.1 µg/dose to 10 µg/dose.

11.3727411LASSA VACCINE
EP - 28.10.2020
Int.Class A61K 35/76 Appl.No 18857393 Applicant PASTEUR INSTITUT Inventor MATEO MATHIEU
The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.

12.20200338187PCV/MYCOPLASMA HYOPNEUMONIAE VACCINE
US - 29.10.2020
Int.Class A61K 39/12 Appl.No 16860308 Applicant Zoetis Services LLC Inventor Gregory P. Nitzel

This invention provides a combination vaccine which includes a porcine circovirus type 2 (PCV2) antigen and a cell free *Mycoplasma hyopneumoniae* (M.hyo) culture supernatant for protecting a pig against PCV2 and M.hyo infections, wherein the M.hyo culture supernatant is substantially free of PCV2 antibodies.

13.WO/2020/220014KLEBSIELLA VACCINE AND METHODS OF USE
WO - 29.10.2020
Int.Class C07H 2/104 Appl.No PCT/US2020/030038 Applicant CORNELL UNIVERSITY Inventor BICALHO, Rodrigo
Provided are compositions and methods that include a K. pneumoniae yidR protein or an antigenic segment of the protein, and homologous of the protein, and antigenic segments of the homologs. The compositions can be provided as vaccine formulations for use with humans and non-human animals, including but not limited to dairy cows. The compositions and methods are useful for prophylaxis and/or therapy of conditions associated with Gram negative bacteria that include K. pneumonia, E. coli, and other pathogenic Gram negative bacteria. The conditions include such bacterial infections generally, and include specifically mastitis and metritis. The compositions and methods can also improve fertility and milk production. Administration of the compositions can improve the likelihood of a first service conception.

14.3728647DETECTION OF MODIFIED LIVE SWINE INFLUENZA VIRUS VACCINES
EP - 28.10.2020
Int.Class C12Q 1/70 Appl.No 18815732 Applicant BOEHRINGER INGELHEIM VETMEDICA GMBH Inventor MOLAU-BLAZEJEWSKA PAULINA
The present invention relates i.a. to diagnostic kits and methods for detecting an animal vaccinated with a modified live Swine Influenza virus specific vaccine and diagnostic kits and methods for differentiating animals vaccinated with a modified live Swine Influenza virus specific vaccine from animals infected with Swine Influenza virus, respectively.

15.3727444SWINE INFLUENZA A VIRUS VACCINE
EP - 28.10.2020
Int.Class A61K 39/193 Appl.No 18830436 Applicant INTERVET INT BV Inventor MOGLER MARK A

The present invention provides vectors and/or nucleic acid constructs that encode one or more influenza A virus neuraminidase (NA) antigens. The present invention also provides vaccine against influenza A virus comprising such vectors and/or nucleic acid constructs. The present invention further provides methods of making and using the vaccines alone, or in combination with other protective agents.

16.3727441METHODS AND APPARATUS FOR THE DELIVERY OF HEPATITIS B VIRUS (HBV) VACCINES
EP - 28.10.2020
Int.Class A61K 39/12 Appl.No 18830986 Applicant JANSSEN SCIENCES IRELAND UNLIMITED CO Inventor BODEN DANIEL
Methods and apparatus for the reproducible, consistent and efficacious delivery of an HBV vaccine to a subject. The disclosure comprises apparatus for the controlled administration of the HBV vaccine through an orifice to the subject, a plurality of penetrating electrodes arranged with a predetermined spatial relationship relative to the orifice, and an electrical signal generator operatively connected to the electrodes.

17.3727431IMPROVED DILUENT FOR CELL-ASSOCIATED ALPHAHERPESVIRUS VACCINE
EP - 28.10.2020
Int.Class A61K 39/00 Appl.No 18833414 Applicant INTERVET INT BV Inventor DE GROOF AD
The present invention relates to the use of a diluent for the in-use stabilisation of cells infected with a cell-associated alphaherpesvirus. Contrary to the long-standing practice of incorporating a considerable amount of peptone into the diluent for such virus-infected cells, it was found that a reduction of the amount of protein in the diluent improved the in-use stability of alphaherpesvirus-infected cells. Whereby the best stability was even obtained using a protein-free diluent. This effect was especially pronounced for recombinant HVT viruses expressing a heterologous insert. Being protein-free is highly advantageous for the production of the diluent, in respect of costs, safety, and consistency of production.

18.3727446METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
EP - 28.10.2020
Int.Class A61K 39/29 Appl.No 18839618 Applicant JANSSEN SCIENCES IRELAND UNLIMITED CO Inventor BODEN DANIEL
Provided herein are Modified Vaccinia Ankara (MVA) vectors and adenovirus vectors encoding HBV antigens. Also provided are methods of enhancing an immune response in a human subject by utilizing the MVA and adenovirus vectors encoding HBV antigens in a prime/boost regimen to the enhance the immune response in the human subject.

19.20200339657PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS
US - 29.10.2020
Int.Class C07K 14/74 Appl.No 16916217 Applicant Immatics Biotechnologies GmbH Inventor Juliane Sarah WALZ

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides

bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

20.3730620CROSS-IMMUNIZING ANTIGEN VACCINE AND METHOD FOR PREPARATION THEREOF
EP - 28.10.2020
Int.Class C12N 15/62 Appl.No 18892222 Applicant GREEN BIOMED INC Inventor SEKIKAWA KENJI
The present invention provides a fusion polypeptide that induces a humoral immune response and a cellular immune response to a virus, containing antigens or fragments thereof of the following (a) and (b), and having an oligomerization activity:(a) an antigen of the virus or a fragment thereof containing a B cell epitope conserved among subtypes of the virus; and(b) an antigen of the virus or a fragment thereof containing a T cell epitope conserved among subtypes of the virus(wherein the antigen(s) or the fragment(s) thereof of (a) and/or (b) have an oligomerization activity, or the fusion polypeptide further contains (c) a polypeptide having an oligomerization activity in addition to the antigens or the fragments thereof (a) and (b)).

21.20200339656PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS
US - 29.10.2020
Int.Class C07K 14/74 Appl.No 16915797 Applicant Immatics Biotechnologies GmbH Inventor Juliane Sarah WALZ

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

22.20200339646B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
US - 29.10.2020
Int.Class C07K 14/47 Appl.No 16916443 Applicant Immatics Biotechnologies GmbH Inventor Colette SONG

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

23.20200338126NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
US - 29.10.2020
Int.Class A61K 35/17 Appl.No 16913788 Applicant Immatics Biotechnologies GmbH Inventor Colette SONG

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

24.20200338186FELINE CALICIVIRUS VACCINE
US - 29.10.2020
Int.Class A61K 39/12 Appl.No 16759945 Applicant Intervet Inc. Inventor Ian Tarpey

The present invention provides new feline calicivirus vaccines, including multivalent vaccines. The present invention also provides methods of making and using the vaccines.

25.20200339652TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
US - 29.10.2020
Int.Class C07K 14/725 Appl.No 16813248 Applicant IMMATICS BIOTECHNOLOGIES GMBH Inventor Dominik MAURER

Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

26.20200339644B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
US - 29.10.2020
Int.Class C07K 14/47 Appl.No 16916432 Applicant Immatics Biotechnologies GmbH Inventor Colette SONG

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

27.WO/2020/218829FLAGELLIN FUSION PROTEIN AND USE THEREOF

  

WO - 29.10.2020
Int.Class C07K 14/195 Appl.No PCT/KR2020/005327 Applicant INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY Inventor CHO, Kyung A
The present invention relates to a flagellin fusion protein and a use thereof and, more specifically, to a fusion protein comprising: flagellin, a fragment thereof, or a variant thereof; and an immunoglobulin Fc region, and a use in which a toll-like receptor 5 (TLR5) stimulating activity thereof is used. The fusion protein provided by the present invention has remarkably excellent toll-like receptor 5 (TLR5) pathway activation ability compared to wild-type flagellin, a fragment thereof, or a variant thereof, and therefore can be greatly utilized to develop a therapeutic agent and/or a vaccine adjuvant for a disease that can be prevented, improved, or treated through activation of the TLR5 pathway.

28.20200339661TRIBLOCK PEPTIDE AMPHIPHILES, MICELLES AND METHODS OF USE
US - 29.10.2020
Int.Class C07K 14/77 Appl.No 16760329 Applicant BRET ULERY Inventor BRET ULERY

One aspect of the present invention is directed to triblock peptides comprising a lipid moiety, a peptide block and a zwittenon-like block. Another aspect of the invention is directed to pharmaceutical compositions comprising the triblock peptides of the present in invention arranged in micelles in a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical compositions of the present invention are vaccine compositions, which may further comprise an adjuvant. Another aspect of the invention is directed to methods of using the triblock peptides and compositions of the invention to treat a disease or condition.

29.20200338188IMMUNIZATIONS OF AVIANS BY ADMINISTRATION OF NON-REPLICATING VECTORED VACCINES
US - 29.10.2020
Int.Class A61K 39/12 Appl.No 16926428 Applicant Altimmune, Inc. Inventor De-Chu C Tang

The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.

30.20200339658PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS
US - 29.10.2020
Int.Class C07K 14/74 Appl.No 16916220 Applicant Immatics Biotechnologies GmbH Inventor Juliane Sarah WALZ

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

31.20200338190HUMAN CYTOMEGALOVIRUS VACCINE
US - 29.10.2020
Int.Class A61K 39/245 Appl.No 16864566 Applicant ModernaTX, Inc. Inventor Giuseppe Ciaramella

The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

32.20200339630PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS
US - 29.10.2020
Int.Class C07K 7/08 Appl.No 16915354 Applicant Immatics Biotechnologies GmbH Inventor Andrea MAHR

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

33.20200339650Tolerogenic DNA Vaccine
US - 29.10.2020
Int.Class C07K 14/62 Appl.No 16395865 Applicant Novo Nordisk A/S Inventor Jay Chaplin

The present invention relates to plasmids useful for prevention and/or delay of e.g. type 1 diabetes.

34.20200339645B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
US - 29.10.2020
Int.Class C07K 14/47 Appl.No 16916438 Applicant Immatics Biotechnologies GmbH Inventor Colette SONG

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

35.20200338175NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS
US - 29.10.2020
Int.Class A61K 39/00 Appl.No 16915323 Applicant Immatics Biotechnologies GmbH Inventor Toni WEINSCHENK

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention

furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

36.20200339555THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
US - 29.10.2020
Int.Class C07D 413/14 Appl.No 16856588 Applicant Regents of the University of Minnesota Inventor Sunil A. David

The invention provides a compound of formula I:

or a salt thereof, wherein $R^1$, $R^2$, $R^3$, A and n have any of the values described in the specification, as well as compositions comprising a compound of formula I, and methods of preparing and use thereof. The compounds are useful as vaccine adjuvant potentiators.

# Patentes registradas en la United States Patent and Trademark Office (USPTO)

*Results of Search in US Patent Collection db for: (ABST/vaccine AND ISD/20201024->20201031), 8 records.*

| | PAT. NO. | Title |
|---|---|---|
| 1 | 10,815,463 | Messenger UNA molecules and uses thereof |
| 2 | 10,815,458 | Methods for inducing migration by dendritic cells and an immune response |
| 3 | 10,815,290 | NKG2D decoys |
| 4 | 10,813,993 | Display platform from bacterial spore coat proteins |
| 5 | 10,813,988 | Pathogen vaccines and methods of producing and using the same |
| 6 | 10,813,986 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| 7 | 10,813,985 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) |
| 8 | 10,813,953 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |

  

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES

  